Erectile Dysfunction (ED) Guideline - American Urological Association (2024)

1. Shea BJ, Hamel C, Wells GA et al: AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews. J Clin Epidemiol 2009; 62: 1013.

2. Cochrane handbook for systematic reviews of interventions. Chichester, West Sussex; Hoboken, NJ: John Wiley & Sons 2008.

3. Faraday M, Hubbard H, Kosiak B et al: Staying at the cutting edge: a review and analysis of evidence reporting and grading; the recommendations of the American Urological Association. BJU Int 2009; 104: 294.

4. Hsu C and Sandford B: The Delphi technique: making sense of consensus. Practical Assessment, Research & Evaluation 2007; 12: 1.

5. Impotence. NIH Consensus Statement 1992; 10: 1.

6. McCabe MP, Sharlip ID, Atalla E et al: Definitions of sexual dysfunctions in women and men: a consensus statement from the Fourth International Consultation on Sexual Medicine 2015. J Sex Med 2016; 13: 135.

7. Saigal CS, Wessells H, Pace J et al: Predictors and prevalence of erectile dysfunction in a racially diverse population. Arch Intern Med 2006; 166: 207.

8. Bacon CG, Mittleman MA, Kawachi I et al: A prospective study of risk factors for erectile dysfunction. J Urol 2006; 176: 217.

9. Elwyn G, Frosch D, Thomson R et al: Shared decision making: a model for clinical practice. J Gen Intern Med 2012; 27: 1361.

10. Epstein RM, Alper BS and Quill TE: Communicating evidence for participatory decision making. JAMA 2004;291: 2359.

11. Hoffmann TC and Del Mar C: Patients' expectations of the benefits and harms of treatments, screening, and tests: a systematic review. JAMA Intern Med 2015; 175: 274.

12. Hatzichristou D, Rosen RC, Derogatis LR et al: Recommendations for the clinical evaluation of men and women with sexual dysfunction. J Sex Med 2010; 7: 337.

13. Vemulakonda VM, Sorensen MD and Joyner BD: The current state of diversity and multicultural training in urology residency programs. J Urol 2008; 180: 668.

14. McKinlay JB: The worldwide prevalence and epidemiology of erectile dysfunction. Int J Impot Res 2000; 12 Suppl 4: S6.

15. Ayta IA, McKinlay JB and Krane RJ: The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int 1999; 84: 50.

16. Jackson G, Boon N, Eardley I et al: Erectile dysfunction and coronary artery disease prediction: evidence-based guidance and consensus. Int J Clin Pract 2010; 64: 848.

17. Martin-Morales A, Sanchez-Cruz JJ, Saenz de Tejada I et al: Prevalence and independent risk factors for erectile dysfunction in Spain: results of the epidemiologia de la disfuncion erectil masculina study. J Urol 2001; 166: 569.

18. Corona G, Lee DM, Forti G et al: Age-related changes in general and sexual health in middle-aged and older men: results from the European Male Ageing Study (EMAS). J Sex Med 2010; 7: 1362.

19. Feldman HA, Goldstein I, Hatzichristou DG et al: Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151: 54.

20. Grover SA, Lowensteyn I, Kaouache M et al: The prevalence of erectile dysfunction in the primary care setting: importance of risk factors for diabetes and vascular disease. Arch Intern Med 2006; 166: 213.

21. Sasayama S, Ishii N, Ishikura F et al: Men's health study: epidemiology of erectile dysfunction and cardiovascular disease. Circ J 2003; 67: 656.

22. Kloner RA: Erectile dysfunction in the cardiac patient. Curr Urol Rep 2003; 4: 466.

23. Montorsi P, Ravagnani PM, Galli S et al: The triad of endothelial dysfunction, cardiovascular disease, and erectile dysfunction: clinical implications. European Urology, Supplements 2009; 8: 58.

24. El-Sakka AI: Association of risk factors and medical comorbidities with male sexual dysfunctions. J Sex Med 2007; 4: 1691.

25. Hodges LD, Kirby M, Solanki J et al: The temporal relationship between erectile dysfunction and cardiovascular disease. Int J Clin Pract 2007; 61: 2019.

26. Montorsi F, Briganti A, Salonia A et al: Erectile dysfunction prevalence, time of onset and association with risk factors in 300 consecutive patients with acute chest pain and angiographically documented coronary artery disease. Eur Urol 2003; 44: 360.

27. Inman BA, Sauver JL, Jacobson DJ et al: A population-based, longitudinal study of erectile dysfunction and future coronary artery disease. Mayo Clin Proc 2009; 84: 108.

28. Fung MM, Bettencourt R and Barrett-Connor E: Heart disease risk factors predict erectile dysfunction 25 years later: the Rancho Bernardo Study. J Am Coll Cardiol 2004; 43: 1405.

29. Esposito K, Giugliano F, Martedi E et al: High proportions of erectile dysfunction in men with the metabolic syndrome. Diabetes Care 2005; 28: 1201.

30. Ansong KS, Lewis C, Jenkins P et al: Epidemiology of erectile dysfunction: a community-based study in rural New York state. Ann Epidemiol 2000; 10: 293.

31. Nwanko T, Yoon S, Burt V et al: Hypertension among adults in the United States: National Health and Nutrition Examination Survey, 2011-2012. Hyattsville, MD: National Center for Health Statistics 2013.

32. Selvin E, Burnett AL and Platz EA: Prevalence and risk factors for erectile dysfunction in the US. Am J Med 2007; 120: 151.

33. Seftel AD, Sun P and Swindle R: The prevalence of hypertension, hyperlipidemia, diabetes mellitus and depression in men with erectile dysfunction. J Urol 2004; 171: 2341.

34. Rosen RC, Fisher WA, Eardley I et al: The Multinational Men's Attitudes to Life Events and Sexuality (MALES) Study: I. Prevalence of erectile dysfunction and related health concerns in the general population. Curr Med Res Opin 2004; 20: 607.

35. Manolis A and Doumas M: Sexual dysfunction: the 'prima ballerina' of hypertension-related quality-of-life complications. J Hypertens 2008; 26: 2074.

36. Toth PP, Potter D and Ming EE: Prevalence of lipid abnormalities in the United States: The National Health and Nutrition Examination Survey 2003-2006. J Clin Lipidol 2012; 6: 325.

37. Eaton CB, Liu YL, Mittleman MA et al: A retrospective study of the relationship between biomarkers of atherosclerosis and erectile dysfunction in 988 men. Int J Impot Res 2007; 19: 218.

38. Romeo JH, Seftel AD, Madhun ZT et al: Sexual function in men with diabetes type 2: association with glycemic control. J Urol 2000; 163: 788.

39. Bacon CG, Hu FB, Giovannucci E et al: Association of type and duration of diabetes with erectile dysfunction in a large cohort of men. Diabetes Care 2002; 25: 1458.

40. Braun MH, Sommer F, Haupt G et al: Lower urinary tract symptoms and erectile dysfunction: co-morbidity or typical "aging male" symptoms? Results of the "Cologne Male Survey." Eur Urol 2003; 44: 588.

41. Hoesl CE, Woll EM, Burkart M et al: Erectile dysfunction (ED) is prevalent, bothersome and underdiagnosed in patients consulting urologists for benign prostatic syndrome (BPS). Eur Urol 2005; 47: 511.

42. Rosen R, Altwein J, Boyle P et al: Lower urinary tract symptoms and male sexual dysfunction: the Multinational Survey of the Aging Male (MSAM-7). Eur Urol 2003; 44: 637.

43. Gonzalez RR and Kaplan SA: Tadalafil for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. Expert Opin Drug Metab Toxicol 2006; 2: 609.

44. Kaplan HS: The new sex therapy: active treatment of sexual dysfunctions: Brunner/Mazel 1974.

45. Masters W, Johnson, V: Human sexual response. New York, NY: Little, Brown and Co. 1966.

46. Marwick C: Survey says patients expect little physician help on sex. JAMA 1999; 281: 2173.

47. Althof SE, Rosen RC, Perelman MA et al: Standard operating procedures for taking a sexual history. J Sex Med 2013; 10: 26.

48. Serefoglu EC, McMahon CG, Waldinger MD et al: An evidence-based unified definition of lifelong and acquired premature ejacul*tion: report of the second International Society for Sexual Medicine Ad Hoc Committee for the Definition of Premature ejacul*tion. Sex Med 2014; 2: 41.

49. Lee JH, Ngengwe R, Jones P et al: Erectile dysfunction as a coronary artery disease risk equivalent. J Nucl Cardiol 2008; 15: 800.

50. Fillo J, Levcikova M, Ondrusova M et al: Importance of different grades of abdominal obesity on testosterone level, erectile dysfunction, and clinical coincidence. Am J Mens Health 2017; 11: 240.

51. Ghanem HM, Salonia A and Martin-Morales A: SOP: physical examination and laboratory testing for men with erectile dysfunction. J Sex Med 2013; 10: 108.

52. McCabe MP and Althof SE: A systematic review of the psychosocial outcomes associated with erectile dysfunction: does the impact of erectile dysfunction extend beyond a man's inability to have sex? J Sex Med 2014; 11: 347.

53. Corona G, Petrone L, Mannucci E et al: Assessment of the relational factor in male patients consulting for sexual dysfunction: the concept of couple sexual dysfunction. J Androl 2006; 27: 795.

54. McCabe M, Althof SE, Assalian P et al: Psychological and interpersonal dimensions of sexual function and dysfunction. J Sex Med 2010; 7: 327.

55. Jannini EA, Isidori AM, Aversa A et al: Which is first? The controversial issue of precedence in the treatment of male sexual dysfunctions. J Sex Med 2013; 10: 2359.

56. Althof SE, Buvat J, Gutkin SW et al: Sexual satisfaction in men with erectile dysfunction: correlates and potential predictors. J Sex Med 2010; 7: 203.

57. Mulhall JP, Goldstein I, Bushmakin AG et al: Validation of the erection hardness score. J Sex Med 2007; 4: 1626.

58. Rosen RC, Cappelleri JC, Smith MD et al: Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 1999; 11: 319.

59. Rosen RC, Riley A, Wagner G et al: The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 822.

60. Cappelleri JC, Rosen RC, Smith MD et al: Diagnostic evaluation of the erectile function domain of the International Index of Erectile Function. Urology 1999; 54: 346.

61. Rosen RC, Allen KR, Ni X et al: Minimal clinically important differences in the erectile function domain of the International Index of Erectile Function scale. Eur Urol 2011; 60: 1010.

62. Rosen RC, Catania J, Pollack L et al: Male Sexual Health Questionnaire (MSHQ): scale development and psychometric validation. Urology 2004; 64: 777.

63. Rosen RC, Catania JA, Althof SE et al: Development and validation of four-item version of Male Sexual Health Questionnaire to assess ejacul*tory dysfunction. Urology 2007; 69: 805.

64. Dong JY, Zhang YH and Qin LQ: Erectile dysfunction and risk of cardiovascular disease: meta-analysis of prospective cohort studies. J Am Coll Cardiol 2011; 58: 1378.

65. Vlachopoulos CV, Terentes-Printzios DG, Ioakeimidis NK et al: Prediction of cardiovascular events and all-cause mortality with erectile dysfunction: a systematic review and meta-analysis of cohort studies. Circ Cardiovasc Qual Outcomes 2013; 6: 99.

66. Thompson IM, Tangen CM, Goodman PJ et al: Erectile dysfunction and subsequent cardiovascular disease. JAMA 2005; 294: 2996.

67. Montorsi P, Ravagnani PM, Galli S et al: Association between erectile dysfunction and coronary artery disease. Role of coronary clinical presentation and extent of coronary vessels involvement: The COBRA trial. Eur Heart J 2006; 27: 2632.

68. Hotaling JM, Walsh TJ, Macleod LC et al: Erectile dysfunction is not independently associated with cardiovascular death: data from the Vitamins and Lifestyle (VITAL) Study. J Sex Med 2012; 9: 2104.

69. Nehra A, Jackson G, Miner M et al: The Princeton III consensus recommendations for the management of erectile dysfunction and cardiovascular disease. Mayo Clin Proc 2012; 87: 766.

70. Hippisley-Cox J, Coupland C and Brindle P: Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ 2017; 357: j2099.

71. Dahabreh IJ and Paulus JK: Association of episodic physical and sexual activity with triggering of acute cardiac events: systematic review and meta-analysis. JAMA 2011; 305: 1225.

72. Wu FC, Tajar A, Beynon JM et al: Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med 2010; 363: 123.

73. Brambilla DJ, O'Donnell AB, Matsumoto AM et al: Intraindividual variation in levels of serum testosterone and other reproductive and adrenal hormones in men. Clin Endocrinol (Oxf) 2007; 67: 853.

74. Brambilla DJ, Matsumoto AM, Araujo AB et al: The effect of diurnal variation on clinical measurement of serum testosterone and other sex hormone levels in men. J Clin Endocrinol Metab 2009; 94: 907.

75. Welliver RC, Jr., Wiser HJ, Brannigan RE et al: Validity of midday total testosterone levels in older men with erectile dysfunction. J Urol 2014; 192: 165.

76. Woolf PD, Hamill RW, McDonald JV et al: Transient hypogonadotropic hypogonadism caused by critical illness. J Clin Endocrinol Metab 1985; 60: 444.

77. Birthi P, Nagar VR, Nickerson R et al: Hypogonadism associated with long-term opioid therapy: a systematic review. J Opioid Manag 2015; 11: 255.

78. Elhanbly S and Elkholy A: Nocturnal penile erections: the role of Rigiscan in the diagnosis of vascular erectile dysfunction. J Sex Med 2012; 9: 3219.

79. Jannini EA, Granata AM, Hatzimouratidis K et al: Use and abuse of Rigiscan in the diagnosis of erectile dysfunction. J Sex Med 2009; 6: 1820.

80. Sikka SC, Hellstrom WJ, Brock G et al: Standardization of vascular assessment of erectile dysfunction: standard operating procedures for duplex ultrasound. J Sex Med 2013; 10: 120.

81. Vruggink PA, Diemont WL, Debruyne FM et al: Enhanced pharmacological testing in patients with erectile dysfunction. J Androl 1995; 16: 163.

82. Diederichs W, Stief CG, Lue TF et al: Sympathetic inhibition of papaverine induced erection. J Urol 1991; 146: 195.

83. Elhanbly S, Schoor R, Elmogy M et al: What nonresponse to intracavernous injection really indicates: a determination by quantitative analysis. J Urol 2002; 167: 192.

84. Lehmann K, John H, Kacl G et al: Variable response to intracavernous prostaglandin E1 testing for erectile dysfunction. Urology 1999; 54: 539.

85. Souper R, Hartmann J, Alvarez M et al: Correlation between peak systolic velocity and diameter of cavernosal arteries in flaccid versus dynamic state for the evaluation of erectile dysfunction. Int J Impot Res 2017; 29: 132.

86. Papagiannopoulos D, Khare N and Nehra A: Evaluation of young men with organic erectile dysfunction. Asian J Androl 2015; 17: 11.

87. Ioakeimidis N, Vlachopoulos C, Rokkas K et al: Dynamic penile peak systolic velocity predicts major adverse cardiovascular events in hypertensive patients with erectile dysfunction. J Hypertens 2016; 34: 860.

88. Spiliopoulos S, Shaida N, Katsanos K et al: The role of interventional radiology in the diagnosis and management of male impotence. Cardiovasc Intervent Radiol 2013; 36: 1204.

89. Giuliano F and Rowland DL: Standard operating procedures for neurophysiologic assessment of male sexual dysfunction. J Sex Med 2013; 10: 1205.

90. Banner LL and Anderson RU: Integrated sildenafil and cognitive-behavior sex therapy for psychogenic erectile dysfunction: a pilot study. J Sex Med 2007; 4: 1117.

91. Melnik T, Abdo CH, de Moraes JF et al: Satisfaction with the treatment, confidence and 'naturalness' in engaging in sexual activity in men with psychogenic erectile dysfunction: preliminary results of a randomized controlled trial of three therapeutic approaches. BJU Int 2012; 109: 1213.

92. Titta M, Tavolini IM, Dal Moro F et al: Sexual counseling improved erectile rehabilitation after non-nerve-sparing radical retropubic prostatectomy or cystectomy--results of a randomized prospective study. J Sex Med 2006; 3: 267.

93. Wylie KR, Jones RH and Walters S: The potential benefit of vacuum devices augmenting psychosexual therapy for erectile dysfunction: a randomized controlled trial. J Sex Marital Ther 2003; 29: 227.

94. McCabe MP, Price E, Piterman L et al: Evaluation of an internet-based psychological intervention for the treatment of erectile dysfunction. Int J Impot Res 2008; 20: 324.

95. van Lankveld JJ, Leusink P, van Diest S et al: Internet-based brief sex therapy for heterosexual men with sexual dysfunctions: a randomized controlled pilot trial. J Sex Med 2009; 6: 2224.

96. Andersson E, Walen C, Hallberg J et al: A randomized controlled trial of guided internet-delivered cognitive behavioral therapy for erectile dysfunction. J Sex Med 2011; 8: 2800.

97.Melnik T, Soares BG and Nasello AG: The effectiveness of psychological interventions for the treatment of erectile dysfunction: systematic review and meta-analysis, including comparisons to sildenafil treatment, intracavernosal injection, and vacuum devices. J Sex Med 2008; 5: 2562. 98. Chambers SK, Occhipinti S, Schover L et al: A randomised controlled trial of a couples-based sexuality intervention for men with localised prostate cancer and their female partners. Psychooncology 2015; 24: 748.

99. Ljunggren C and Stroberg P: Improvement in sexual function after robot-assisted radical prostatectomy: a rehabilitation program with involvement of a clinical sexologist. Cent European J Urol 2015; 68: 214.

100. Esposito K, Giugliano F, Di Palo C et al: Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial. JAMA 2004; 291: 2978.

101. Esposito K, Ciotola M, Giugliano F et al: Mediterranean diet improves erectile function in subjects with the metabolic syndrome. Int J Impot Res 2006; 18: 405.

102. Esposito K, Ciotola M, Giugliano F et al: Effects of intensive lifestyle changes on erectile dysfunction in men. J Sex Med 2009; 6: 243.

103. Collins CE, Jensen ME, Young MD et al: Improvement in erectile function following weight loss in obese men: the SHED-IT randomized controlled trial. Obes Res Clin Pract 2013; 7: e450.

104. Khoo J, Piantadosi C, Worthley S et al: Effects of a low-energy diet on sexual function and lower urinary tract symptoms in obese men. Int J Obes (Lond) 2010; 34: 1396.

105. Khoo J, Tian HH, Tan B et al: Comparing effects of low- and high-volume moderate-intensity exercise on sexual function and testosterone in obese men. J Sex Med 2013; 10: 1823.

106. Wing RR, Rosen RC, Fava JL et al: Effects of weight loss intervention on erectile function in older men with type 2 diabetes in the Look Ahead Trial. J Sex Med 2010; 7: 156.

107. Lamina S, Okoye CG and Dagogo TT: Therapeutic effect of an interval exercise training program in the management of erectile dysfunction in hypertensive patients. J Clin Hypertens (Greenwich) 2009; 11: 125.

108. Begot I, Peixoto TC, Gonzaga LR et al: A home-based walking program improves erectile dysfunction in men with an acute myocardial infarction. Am J Cardiol 2015; 115: 571.

109. Kalka D, Domagala Z, Dworak J et al: Association between physical exercise and quality of erection in men with ischaemic heart disease and erectile dysfunction subjected to physical training. Kardiol Pol 2013; 71: 573.

110. Kalka D, Domagala ZA, Kowalewski P et al: Effect of endurance cardiovascular training intensity on erectile dysfunction severity in men with ischemic heart disease. Am J Mens Health 2015; 9: 360.

111. Kovac JR, Labbate C, Ramasamy R et al: Effects of cigarette smoking on erectile dysfunction. Andrologia 2015; 47: 1087.

112. Afif-Abdo J, Teloken C, Damiao R et al: Comparative cross-over study of sildenafil and apomorphine for treating erectile dysfunction. BJU Int 2008; 102: 829.

113. Ali ST: Effectiveness of sildenafil citrate (Viagra®) and tadalafil (Cialis®) on sexual responses in Saudi men with erectile dysfunction in routine clinical practice. Pak J Pharm Sci 2008; 21: 275.

114. Althof SE, O'Leary M P, Cappelleri JC et al: Sildenafil citrate improves self-esteem, confidence, and relationships in men with erectile dysfunction: results from an international, multi-center, double-blind, placebo-controlled trial. J Sex Med 2006; 3: 521.

115. Bai WJ, Li HJ, Dai YT et al: An open-label, multicenter, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in Chinese men naive to phosphodiesterase 5 inhibitor therapy. Asian J Androl 2015; 17: 61.

116. Bai WJ, Li HJ, Jin JJ et al: A randomized clinical trial investigating treatment choice in Chinese men receiving sildenafil citrate and tadalafil for treating erectile dysfunction. Asian J Androl 2016;

117. Basar M, Tekdogan UY, Yilmaz E et al: The efficacy of sildenafil in different etiologies of erectile dysfunction. Int Urol Nephrol 2001; 32: 403.

118. Becher E, Tejada Noriega A, Gomez R et al: Sildenafil citrate (Viagra) in the treatment of men with erectile dysfunction in southern Latin America: a double-blind, randomized, placebo-controlled, parallel-group, multicenter, flexible-dose escalation study. Int J Impot Res 2002; 14 Suppl 2: S33.

119. Belkoff LH, McCullough A, Goldstein I et al: An open-label, long-term evaluation of the safety, efficacy and tolerability of avanafil in male patients with mild to severe erectile dysfunction. Int J Clin Pract 2013; 67: 333.

120. Benard F, Carrier S, Lee JC et al: Men with mild erectile dysfunction benefit from sildenafil treatment. J Sex Med 2010; 7: 3725.

121. Benchekroun A, Faik M, Benjelloun S et al: A baseline-controlled, open-label, flexible dose-escalation study to assess the safety and efficacy of sildenafil citrate (Viagra) in patients with erectile dysfunction. Int J Impot Res 2003; 15 Suppl 1: S19.

122. Boddi V, Castellini G, Casale H et al: An integrated approach with vardenafil orodispersible tablet and cognitive behavioral sex therapy for treatment of erectile dysfunction: a randomized controlled pilot study. Andrology 2015; 3: 909.

123. Brock G, Carrier S, Alarie P et al: The effect of physician and patient education when combined with vardenafil treatment in Canadian males with erectile dysfunction: an open-label, factorial-designed, cluster-randomized clinical trial. J Sex Med 2008; 5: 705.

124. Brock GB, McMahon CG, Chen KK et al: Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol 2002; 168: 1332.

125. Buvat J, Hatzichristou D, Maggi M et al: Efficacy, tolerability and satisfaction with sildenafil citrate 100-mg titration compared with continued 50-mg dose treatment in men with erectile dysfunction. BJU Int 2008; 102: 1645.

126. Buvat J, Buttner H, Hatzimouratidis K et al: Adherence to initial PDE-5 inhibitor treatment: randomized open-label study comparing tadalafil once a day, tadalafil on demand, and sildenafil on demand in patients with erectile dysfunction. J Sex Med 2013; 10: 1592.

127. Hatzimouratidis K, Buvat J, Buttner H et al: Psychosocial outcomes after initial treatment of erectile dysfunction with tadalafil once daily, tadalafil on demand or sildenafil citrate on demand: results from a randomized, open-label study. Int J Impot Res 2014; 26: 223.

128. Buvat J, Hatzichristou D, Boess FG et al: Continuation and effectiveness of tadalafil once daily during a 6-month observational study in erectile dysfunction: the EDATE Study. Int J Clin Pract 2014; 68: 1087.

129. Carrier S, Brock G, Casey R et al: Treatment satisfaction with sildenafil in a Canadian real-life setting. A 6-month prospective observational study of primary care practices. J Sex Med 2007; 4: 1414.

130. Carrier S, Brock GB, Pommerville PJ et al: Efficacy and safety of oral tadalafil in the treatment of men in Canada with erectile dysfunction: a randomized, double-blind, parallel, placebo-controlled clinical trial. J Sex Med 2005; 2: 685.

131. Carson C, Shabsigh R, Segal S et al: Efficacy, safety, and treatment satisfaction of tadalafil versus placebo in patients with erectile dysfunction evaluated at tertiary-care academic centers. Urology 2005; 65: 353.

132. Carson CC, Rajfer J, Eardley I et al: The efficacy and safety of tadalafil: an update. BJU Int 2004; 93: 1276.

133. Chen KK, Hsieh JT, Huang ST et al: ASSESS-3: a randomised, double-blind, flexible-dose clinical trial of the efficacy and safety of oral sildenafil in the treatment of men with erectile dysfunction in Taiwan. Int J Impot Res 2001; 13: 221.

134. Chen KK, Jiann BP, Lin JS et al: Efficacy and safety of on-demand oral tadalafil in the treatment of men with erectile dysfunction in Taiwan: a randomized, double-blind, parallel, placebo-controlled clinical study. J Sex Med 2004; 1: 201.

135. Cheng E: Real-life safety and efficacy of vardenafil in the treatment of erectile dysfunction-results from 30,010 US patients. J Sex Med 2007; 4: 432.

136. Choi HK, Ahn TY, Kim JJ et al: A double-blind, randomised- placebo, controlled, parallel group, multicentre, flexible-dose escalation study to assess the efficacy and safety of sildenafil administered as required to male outpatients with erectile dysfunction in Korea. Int J Impot Res 2003; 15: 80.

137. Choi HK, Kim JJ, Kim SC et al: A randomised, double-blind, parallel, placebo-controlled study of the efficacy and safety of tadalafil administered on-demand to men with erectile dysfunction in Korea. Korean J Urol 2006; 47: 852.

138. Christiansen E, Guirguis WR, Cox D et al: Long-term efficacy and safety of oral Viagra (sildenafil citrate) in men with erectile dysfunction and the effect of randomised treatment withdrawal. Int J Impot Res 2000; 12: 177.

139. Costa P, Buvat J, Holmes S et al: Predictors of tadalafil efficacy in men with erectile dysfunction: the SURE study comparing two dosing regimens. J Sex Med 2006; 3: 1050.

140. Mirone V, Costa P, Damber JE et al: An evaluation of an alternative dosing regimen with tadalafil, 3 times/week, for men with erectile dysfunction: SURE study in 14 European countries. Eur Urol 2005; 47: 846.

141. Costa P, Grandmottet G, Mai HD et al: Impact of a first treatment with phosphodiesterase inhibitors on men and partners' quality of sexual life: results of a prospective study in primary care. J Sex Med 2013; 10: 1850.

142. Dean J, Hackett GI, Gentile V et al: Psychosocial outcomes and drug attributes affecting treatment choice in men receiving sildenafil citrate and tadalafil for the treatment of erectile dysfunction: results of a multicenter, randomized, open-label, crossover study. J Sex Med 2006; 3: 650.

143. Eardley I, Mirone V, Montorsi F et al: An open-label, multicentre, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in men naive to phosphodiesterase 5 inhibitor therapy. BJU Int 2005; 96: 1323.

144. Dinsmore WW, Hodges M, Hargreaves C et al: Sildenafil citrate (Viagra) in erectile dysfunction: near normalization in men with broad-spectrum erectile dysfunction compared with age-matched healthy control subjects. Urology 1999; 53: 800.

145. Donatucci C, Eardley I, Buvat J et al: Vardenafil improves erectile function in men with erectile dysfunction irrespective of disease severity and disease classification. J Sex Med 2004; 1: 301.

146. Eardley I, Gentile V, Austoni E et al: Efficacy and safety of tadalafil in a western European population of men with erectile dysfunction. BJU Int 2004; 94: 871.

147. Eardley I, Morgan R, Dinsmore W et al: Efficacy and safety of sildenafil citrate in the treatment of men with mild to moderate erectile dysfunction. Br J Psychiatry 2001; 178: 325.

148. Eardley I, Wright P, MacDonagh R et al: An open-label, randomized, flexible-dose, crossover study to assess the comparative efficacy and safety of sildenafil citrate and apomorphine hydrochloride in men with erectile dysfunction. BJU Int 2004; 93: 1271.

149. Edwards D, Hackett G, Collins O et al: Vardenafil improves sexual function and treatment satisfaction in couples affected by erectile dysfunction (ED): a randomized, double-blind, placebo-controlled trial in PDE5 inhibitor-naive men with ED and their partners. J Sex Med 2006; 3: 1028.

150. El Khiat Y, Ghazi S, Allam A et al: Psychosocial impact and effectiveness of tadalafil among treatment-naive and previously-treated men with erectile dysfunction in Saudi Arabia and other Gulf-region countries. Curr Med Res Opin 2008; 24: 1965.

151. fa*gelman E, fa*gelman A and Shabsigh R: Efficacy, safety, and use of sildenafil in urologic practice. Urology 2001; 57: 1141.

152. Zonana Farca E, Francolugo-Velez V, Moy-Eransus C et al: Self-esteem, confidence and relationship satisfaction in men with erectile dysfunction: a randomized, parallel-group, double-blind, placebo-controlled study of sildenafil in Mexico. Int J Impot Res 2008; 20: 402.

153. Fisher WA, Rosen RC, Mollen M et al: Improving the sexual quality of life of couples affected by erectile dysfunction: a double-blind, randomized, placebo-controlled trial of vardenafil. J Sex Med 2005; 2: 699.

154. Goldstein I, Fisher WA, Sand M et al: Women's sexual function improves when partners are administered vardenafil for erectile dysfunction: a prospective, randomized, double-blind, placebo-controlled trial. J Sex Med 2005; 2: 819.

155. Fugl-Meyer KS, Stothard D, Belger M et al: The effect of tadalafil on psychosocial outcomes in Swedish men with erectile distress: a multicentre, non-randomised, open-label clinical study. Int J Clin Pract 2006; 60: 1386.

156. Fujisawa M and Sawada K: Clinical efficacy and safety of sildenafil in elderly patients with erectile dysfunction. Arch Androl 2004; 50: 255.

157. Giammusso B, Colpi GM, Cormio L et al: An open-label, randomized, flexible-dose, crossover study to assess the comparative efficacy and safety of sildenafil citrate and apomorphine hydrochloride in men with erectile dysfunction. Urol Int 2008; 81: 409.

158. Gil A, Martinez E, Oyaguez I et al: Erectile dysfunction in a primary care setting: results of an observational, no-control-group, prospective study with sildenafil under routine conditions of use. Int J Impot Res 2001; 13: 338.

159. Gittelman M, McMahon CG, Rodriguez-Rivera JA et al: The POTENT II randomised trial: efficacy and safety of an orodispersible vardenafil formulation for the treatment of erectile dysfunction. Int J Clin Pract 2010; 64: 594.

160. Giuliano F, Donatucci C, Montorsi F et al: Vardenafil is effective and well-tolerated for treating erectile dysfunction in a broad population of men, irrespective of age. BJU Int 2005; 95: 110.

161. Giuliano F, Montorsi F, Mirone V et al: Switching from intracavernous prostaglandin E1 injections to oral sildenafil citrate in patients with erectile dysfunction: results of a multicenter European study. The Sildenafil Multicenter Study Group. J Urol 2000; 164: 708.

162. Glina S, Bertero E, Claro J et al: Efficacy and safety of flexible-dose oral sildenafil citrate (Viagra) in the treatment of erectile dysfunction in Brazilian and Mexican men. Int J Impot Res 2002; 14 Suppl 2: S27.

163. Glina S, Damiao R, Abdo C et al: Self-esteem, confidence, and relationships in Brazilian men with erectile dysfunction receiving sildenafil citrate: a randomized, parallel-group, double-blind, placebo-controlled study in Brazil. J Sex Med 2009; 6: 268.

164. Cairoli C, Reyes LA, Henneges C et al: PDE5 inhibitor treatment persistence and adherence in Brazilian men: post-hoc analyses from a 6-month, prospective, observational study. Int Braz J Urol 2014; 40: 390.

165. Gokce MI, Gulpinar O, Ozturk E et al: Effect of atorvastatin on erectile functions in comparison with regular tadalafil use. A prospective single-blind study. Int Urol Nephrol 2012; 44: 683.

166. Goldstein I, Kim E, Steers WD et al: Efficacy and safety of tadalafil in men with erectile dysfunction with a high prevalence of comorbid conditions: results from MOMENTUS: multiple observations in men with erectile dysfunction in National Tadalafil Study in the US. J Sex Med 2007; 4: 166.

167. Goldstein I, McCullough AR, Jones LA et al: A randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of avanafil in subjects with erectile dysfunction. J Sex Med 2012; 9: 1122.

168. Goldstein I, Lue TF, Padma-Nathan H et al: Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med 1998; 338: 1397.

169. Goldstein I, Tseng LJ, Creanga D et al: Efficacy and safety of sildenafil by age in men with erectile dysfunction. J Sex Med 2016; 13: 852.

170. Gomez F, Davila H, Costa A et al: Efficacy and safety of oral sildenafil citrate (Viagra) in the treatment of male erectile dysfunction in Colombia, Ecuador, and Venezuela: a double-blind, multicenter, placebo-controlled study. Int J Impot Res 2002; 14 Suppl 2: S42.

171. Govier F, Potempa AJ, Kaufman J et al: A multicenter, randomized, double-blind, crossover study of patient preference for tadalafil 20 mg or sildenafil citrate 50 mg during initiation of treatment for erectile dysfunction. Clin Ther 2003; 25: 2709.

172. Guo YL, Zhu JC, Pan TM et al: Efficacy and safety of on-demand tadalafil for the treatment of erectile dysfunction in South-East Asian men. Int J Urol 2006; 13: 721.

173. Hartmann U, Hanisch JU and Mattern A: The real-life perception of efficacy, attitude, satisfaction and safety of vardenafil therapy (REPEAT): a prospective, non-interventional, observational study. Aging Male 2014; 17: 117.

174. Hatzichristou D, Cuzin B, Martin-Morales A et al: Vardenafil improves satisfaction rates, depressive symptomatology, and self-confidence in a broad population of men with erectile dysfunction. J Sex Med 2005; 2: 109.

175. Hatzichristou D, Montorsi F, Buvat J et al: The efficacy and safety of flexible-dose vardenafil (Levitra) in a broad population of European men. Eur Urol 2004; 45: 634.

176. Hatzichristou D, Vardi Y, Papp G et al: Effect of tadalafil on sexual timing behavior patterns in men with erectile dysfunction: integrated analysis of randomized, placebo controlled trials. J Urol 2005; 174: 1356.

177. Heiman JR, Talley DR, Bailen JL et al: Sexual function and satisfaction in heterosexual couples when men are administered sildenafil citrate (Viagra) for erectile dysfunction: a multicentre, randomised, double-blind, placebo-controlled trial. Bjog 2007; 114: 437.

178. Hellstrom WJ, Gittelman M, Karlin G et al: Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial. J Androl 2002; 23: 763.

179. Hellstrom WJ, Gittelman M, Karlin G et al: Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction: results of a randomized, double-blind, 26-week placebo-controlled pivotal trial. Urology 2003; 61: 8.

180. Huang ST: Use of sildenafil citrate in treatment of Taiwanese men with erectile dysfunction: a single center experience. Chang Gung Med J 2001; 24: 91.

181. Hundertmark J, Esterman A, Ben-Tovim D et al: The South Australian couples sildenafil study: double-blind, parallel-group randomized controlled study to examine the psychological and relationship consequences of sildenafil use in couples. J Sex Med 2007; 4: 1126.

182. Isidori AM, Corona G, Aversa A et al: The SIAMS-ED trial: a national, independent, multicentre study on cardiometabolic and hormonal impairment of men with erectile dysfunction treated with vardenafil. Int J Endocrinol 2014; 2014: doi:10.1155/2014/858715.

183. Jamshidian H, Borhan A, Kooraki S et al: Evaluation of the efficacy of once-daily use of tadalafil vs. on-demand use. Is there a cumulative effect? J Pak Med Assoc 2012; 62: 1195.

184. Jannini EA, Isidori AM, Gravina GL et al: The ENDOTRIAL study: a spontaneous, open-label, randomized, multicenter, crossover study on the efficacy of sildenafil, tadalafil, and vardenafil in the treatment of erectile dysfunction. J Sex Med 2009; 6: 2547.

185. Jarow JP, Burnett AL and Geringer AM: Clinical efficacy of sildenafil citrate based on etiology and response to prior treatment. J Urol 1999; 162: 722.

186. Jarvi K, Dula E, Drehobl M et al: Daily vardenafil for 6 months has no detrimental effects on sem*n characteristics or reproductive hormones in men with normal baseline levels. J Urol 2008; 179: 1060.

187. Jiann BP, Yu CC, Tsai JY et al: What to learn about sildenafil in the treatment of erectile dysfunction from 3-year clinical experience. Int J Impot Res 2003; 15: 412.

188. Jones LA, Klimberg IW, McMurray JG et al: Effect of sildenafil citrate on the male sexual experience assessed with the sexual experience questionnaire: a multicenter, double-blind, placebo-controlled trial with open-label extension. J Sex Med 2008; 5: 1955.

189. Kadioglu A, Grohmann W, Depko A et al: Quality of erections in men treated with flexible-dose sildenafil for erectile dysfunction: multicenter trial with a double-blind, randomized, placebo-controlled phase and an open-label phase. J Sex Med 2008; 5: 726.

190. Kamalov AA, Dorofeev SD, Efremov EA et al: The Russian experience of studying vardenafil efficacy and safety in men with erectile dysfunction of various aetiologies. Journal of Men's Health 2008; 5: 36.

191. Kamel A, Khaouli R, Sabha M et al: The real-life safety and efficacy of vardenafil: an international post-marketing surveillance study of 2824 patients from the Middle East. Clin Drug Investig 2007; 27: 339.

192. Kang DH, Lee JY, Park SY et al: Efficacy and safety of tadalafil 5 mg administered once daily in Korean men with erectile dysfunction: a prospective, multicenter study. Korean J Urol 2010; 51: 647.

193. Kang DH, Lee JY, Chung JH et al: Comparison of efficacy for erectile function and lower urinary tract symptoms of tadalafil 20 mg on-demand and 5 mg once daily in patients with erectile dysfunction. Int J Clin Pract 2012; 66: 813.

194. Kim E, Seftel A, Goldfischer E et al: Efficacy of as needed PDE5 inhibitor therapy vs. tadalafil once daily on improvement in erectile dysfunction. J Sex Med 2014; 11: 176.

195. Seftel AD, Rosen RC, Hayes RP et al: Effect of once-daily tadalafil on confidence and perceived difficulty in performing sexual intercourse in men who were incomplete responders to as-needed PDE5 inhibitor treatment. Int J Clin Pract 2014; 68: 841.

196. Kim E, Seftel A, Goldfischer E et al: Comparative efficacy of tadalafil once daily in men with erectile dysfunction who demonstrated previous partial responses to as-needed sildenafil, tadalafil, or vardenafil. Curr Med Res Opin 2015; 31: 379.

197. Burns PR, Rosen RC, Dunn M et al: Treatment satisfaction of men and partners following switch from on-demand phosphodiesterase type 5 inhibitor therapy to tadalafil 5 mg once daily. J Sex Med 2015; 12: 720.

198. Kim CM, Kim YS, Sunwoo S et al: Post-marketing surveillance study of the efficacy and safety of vardenafil among patients with erectile dysfunction in primary care. Int J Impot Res 2007; 19: 393.

199. Kirby M, Creanga DL and Stecher VJ: Erectile function, erection hardness and tolerability in men treated with sildenafil 100 mg vs. 50 mg for erectile dysfunction. Int J Clin Pract 2013; 67: 1034.

200. Kobayashi K, Hisasue S, Kato R et al: Outcome analysis of sildenafil citrate for erectile dysfunction of Japanese patients. Int J Impot Res 2006; 18: 302.

201. Kongkanand A, Ratana-Olarn K, Ruangdilokrat S et al: The efficacy and safety of oral sildenafil in Thai men with erectile dysfunction: a randomized, double-blind, placebo controlled, flexible-dose study. J Med Assoc Thai 2003; 86: 195.

202. Koulikov D, Fridmans A, Chertin B et al: Is sildenafil citrate associated with an amelioration of the symptomatology of androgen decline in the aging male? J Urol 2007; 177: 2267.

203. Kumar S, Roat R, Agrawal S et al: Combination therapy of tadalafil and pentoxifylline in severe erectile dysfunction: a prospective randomized trial. Pol Przegl Chir 2015; 87: 377.

204. Levinson IP, Khalaf IM, Shaeer KZ et al: Efficacy and safety of sildenafil citrate (Viagra) for the treatment of erectile dysfunction in men in Egypt and South Africa. Int J Impot Res 2003; 15 Suppl 1: S25.

205. Lewis R, Bennett CJ, Borkon WD et al: Patient and partner satisfaction with Viagra (sildenafil citrate) treatment as determined by the erectile dysfunction inventory of treatment satisfaction questionnaire. Urology 2001; 57: 960.

206. Li G, Lan H, Liang J et al: Efficacy of tadalafil de-escalation in the treatment of psychogenic erectile dysfunction. Urol Int 2017; 98: 205.

207. Lim PH, Li MK, Ng FC et al: Clinical efficacy and safety of sildenafil citrate (Viagra) in a multi-racial population in Singapore: a retrospective study of 1520 patients. Int J Urol 2002; 9: 308.

208. Loran OB, Stroberg P, Lee SW et al: Sildenafil citrate 100 mg starting dose in men with erectile dysfunction in an international, double-blind, placebo-controlled study: effect on the sexual experience and reducing feelings of anxiety about the next intercourse attempt. J Sex Med 2009; 6: 2826.

209. Magoha GA: Sildenafil (Viagra) in the treatment of male erectile dysfunction in Nairobi. East Afr Med J 2000; 77: 76.

210. Marks LS, Duda C, Dorey FJ et al: Treatment of erectile dysfunction with sildenafil. Urology 1999; 53: 19.

211. Martin-Morales A, Graziottin A, Jaoude GB et al: Improvement in sexual quality of life of the female partner following vardenafil treatment of men with erectile dysfunction: a randomized, double-blind, placebo-controlled study. J Sex Med 2011; 8: 2831.

212. Martin-Morales A, Gutierrez-Hernandez P, Romero-Otero J et al: Duration of erection: does it really matter? A randomized, double-blind clinical trial to assess the impact of vardenafil ODT on duration of erection and its correlation with patients' and partners' sexual quality of life and duration of intercourse: the VADEOPEN study. J Sex Med 2014; 11: 1527.

213. Martin-Morales A, Haro JM, Beardsworth A et al: Therapeutic effectiveness and patient satisfaction after 6 months of treatment with tadalafil, sildenafil, and vardenafil: results from the erectile dysfunction observational study (EDOS). Eur Urol 2007; 51: 541.

214. Martin-Morales A, Meijide F, Garcia N et al: Efficacy of vardenafil and influence on self-esteem and self-confidence in patients with severe erectile dysfunction. J Sex Med 2007; 4: 440.

215. Martinez-Jabaloyas JM, Gil-Salom M, Villamon-Fort R et al: Prognostic factors for response to sildenafil in patients with erectile dysfunction. Eur Urol 2001; 40: 641.

216. McMahon CG, Samali R and Johnson H: Efficacy, safety and patient acceptance of sildenafil citrate as treatment for erectile dysfunction. J Urol 2000; 164: 1192.

217. McMahon C, Kloner RA, Hutter Jr AM et al: Comparison of efficacy, safety, and tolerability of on-demand tadalafil and daily dosed tadalafil for the treatment of erectile dysfunction. J Sex Med 2005; 2: 415.

218. McMahon C, Lording D, Stuckey B et al: Vardenafil improved erectile function in a "real-life" broad population study of men with moderate to severe erectile dysfunction in Australia and New Zealand. J Sex Med 2006; 3: 892.

219. McMahon CG, Stuckey BG, Lording DW et al: A 6-month study of the efficacy and safety of tadalafil in the treatment of erectile dysfunction: a randomised, double-blind, parallel-group, placebo-controlled study in Australian men. Int J Clin Pract 2005; 59: 143.

220. McMurray JG, Feldman RA, Auerbach SM et al: Long-term safety and effectiveness of sildenafil citrate in men with erectile dysfunction. Ther Clin Risk Manag 2007; 3: 975.

221. Meuleman E, Cuzin B, Opsomer RJ et al: A dose-escalation study to assess the efficacy and safety of sildenafil citrate in men with erectile dysfunction. BJU Int 2001; 87: 75.

222. Mirone V, Palmieri A, Cucinotta D et al: Flexible-dose vardenafil in a community-based population of men affected by erectile dysfunction: a 12-week open-label, multicenter trial. J Sex Med 2005; 2: 842.

223. Moncada I, Martinez-Jabaloyas JM, Rodriguez-Vela L et al: Emotional changes in men treated with sildenafil citrate for erectile dysfunction: a double-blind, placebo-controlled clinical trial. J Sex Med 2009; 6: 3469.

224. Montorsi F and Althof SE: Partner responses to sildenafil citrate (Viagra) treatment of erectile dysfunction. Urology 2004; 63: 762.

225. Montorsi F, Aversa A, Moncada I et al: A randomized, double-blind, placebo-controlled, parallel study to assess the efficacy and safety of once-a-day tadalafil in men with erectile dysfunction who are naive to PDE5 inhibitors. J Sex Med 2011; 8: 2617.

226. Porst H, Brock GB, Kula K et al: Effects of once-daily tadalafil on treatment satisfaction, psychosocial outcomes, spontaneous erections, and measures of endothelial function in men with erectile dysfunction but naive to phosphodiesterase type 5 inhibitors. J Androl 2012; 33: 1305.

227. Montorsi F, Hellstrom WJ, Valiquette L et al: Vardenafil provides reliable efficacy over time in men with erectile dysfunction. Urology 2004; 64: 1187.

228. Montorsi F, McDermott TE, Morgan R et al: Efficacy and safety of fixed-dose oral sildenafil in the treatment of erectile dysfunction of various etiologies. Urology 1999; 53: 1011.

229. Montorsi F, Padma-Nathan H, Buvat J et al: Earliest time to onset of action leading to successful intercourse with vardenafil determined in an at-home setting: a randomized, double-blind, placebo-controlled trial. J Sex Med 2004; 1: 168.

230. Montorsi F, Verheyden B, Meuleman E et al: Long-term safety and tolerability of tadalafil in the treatment of erectile dysfunction. Eur Urol 2004; 45: 339.

231. Moreira SG, Jr., Brannigan RE, Spitz A et al: Side-effect profile of sildenafil citrate (Viagra) in clinical practice. Urology 2000; 56: 474.

232. Morgentaler A, Barada J, Niederberger C et al: Efficacy and safety of tadalafil across ethnic groups and various risk factors in men with erectile dysfunction: use of a novel noninferiority study design. J Sex Med 2006; 3: 492.

233. Gomery P, Bullock A, McGettigan J et al: Tadalafil is efficacious in Black American and Hispanic men with erectile dysfunction: results from multiple observations in men with erectile dysfunction in national tadalafil study in the US (MOMENTUS). Int J Impot Res 2007; 19: 76.

234. Muller A, Smith L, Parker M et al: Analysis of the efficacy and safety of sildenafil citrate in the geriatric population. BJU Int 2007; 100: 117.

235. Nagao K, Ishii N, Kamidono S et al: Safety and efficacy of vardenafil in patients with erectile dysfunction: result of a bridging study in Japan. Int J Urol 2004; 11: 515.

236. Nagao K, Kimoto Y, Marumo K et al: Efficacy and safety of tadalafil 5, 10, and 20 mg in Japanese men with erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled study. Urology 2006; 68: 845.

237. O'Leary MP, Althof SE, Cappelleri JC et al: Self-esteem, confidence and relationship satisfaction of men with erectile dysfunction treated with sildenafil citrate: a multicenter, randomized, parallel group, double-blind, placebo controlled study in the United States. J Urol 2006; 175: 1058.

238. Ochiai A, Naya Y, Soh J et al: Efficacy of sildenafil as the first-step therapeutic tool for Japanese patients with erectile dysfunction. Int J Impot Res 2005; 17: 339.

239. Olsson AM, Speakman MJ, Dinsmore WW et al: Sildenafil citrate (Viagra) is effective and well tolerated for treating erectile dysfunction of psychogenic or mixed aetiology. Int J Clin Pract 2000; 54: 561.

240. Osegbe DN, sh*ttu OB, Aghaji AE et al: Sildenafil citrate (Viagra) for the treatment of erectile dysfunction in Nigerian men. Int J Impot Res 2003; 15 Suppl 1: S15.

241. Padma-Nathan H, McMurray JG, Pullman WE et al: On-demand IC351 (Cialis) enhances erectile function in patients with erectile dysfunction. Int J Impot Res 2001; 13: 2.

242. Padma-Nathan H, Steers WD and Wicker PA: Efficacy and safety of oral sildenafil in the treatment of erectile dysfunction: a double-blind, placebo-controlled study of 329 patients. Sildenafil Study Group. Int J Clin Pract 1998; 52: 375.

243. Palumbo F, Bettocchi C, Selvaggi FP et al: Sildenafil: efficacy and safety in daily clinical experience. Eur Urol 2001; 40: 176.

244. Pavone C, Curto F, Anello G et al: Prospective, randomized, crossover comparison of sublingual apomorphine (3 mg) with oral sildenafil (50 mg) for male erectile dysfunction. J Urol 2004; 172: 2347.

245. Perimenis P, Gyftopoulos K, Giannitsas K et al: A comparative, crossover study of the efficacy and safety of sildenafil and apomorphine in men with evidence of arteriogenic erectile dysfunction. Int J Impot Res 2004; 16: 2.

246. Perimenis P, Markou S, Gyftopoulos K et al: Efficacy of apomorphine and sildenafil in men with nonarteriogenic erectile dysfunction. A comparative crossover study. Andrologia 2004; 36: 106.

247. Porst H, Behre HM, Jungwirth A et al: Comparative trial of treatment satisfaction, efficacy and tolerability of sildenafil versus apomorphine in erectile dysfunction--an open, randomized cross-over study with flexible dosing. Eur J Med Res 2007; 12: 61.

248. Porst H, Gacci M, Buttner H et al: Tadalafil once daily in men with erectile dysfunction: an integrated analysis of data obtained from 1913 patients from six randomized, double-blind, placebo-controlled, clinical studies. Eur Urol 2014; 65: 455.

249. Porst H, Giuliano F, Glina S et al: Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5mg and 10mg in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial. Eur Urol 2006; 50: 351.

250. Porst H, Rajfer J, Casabe A et al: Long-term safety and efficacy of tadalafil 5 mg dosed once daily in men with erectile dysfunction. J Sex Med 2008; 5: 2160.

251. Porst H, Rosen R, Padma-Nathan H et al: The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial. Int J Impot Res 2001; 13: 192.

502. Zotz RB, Finger C, Scharf RE et al: Associations between thrombophilic risk factors and determinants of atherosclerosis and inflammation in patients with non-arteritic anterior ischaemic optic neuropathy. Hamostaseologie 2016; 36: 46.

503. Campbell UB, Walker AM, Gaffney M et al: Acute nonarteritic anterior ischemic optic neuropathy and exposure to phosphodiesterase type 5 inhibitors. J Sex Med 2015; 12: 139.

504. Margo CE and French DD: Ischemic optic neuropathy in male veterans prescribed phosphodiesterase-5 inhibitors. Am J Ophthalmol 2007; 143: 538.

505. Flahavan EM, Li H, Gupte-Singh K et al: Prospective case-crossover study investigating the possible association between nonarteritic anterior ischemic optic neuropathy and phosphodiesterase type 5 inhibitor exposure. Urology 2017; 105: 76.

506. Pomeranz HD: The relationship between phosphodiesterase-5 inhibitors and nonarteritic anterior ischemic optic neuropathy. J Neuroophthalmol 2016; 36: 193.

507. Li WQ, Qureshi AA, Robinson KC et al: Sildenafil use and increased risk of incident melanoma in US men: a prospective cohort study. JAMA Intern Med 2014; 174: 964.

508. Loeb S, Folkvaljon Y, Lambe M et al: Use of phosphodiesterase type 5 inhibitors for erectile dysfunction and risk of malignant melanoma. JAMA 2015; 313: 2449.

509. Lian Y, Yin H, Pollak MN et al: Phosphodiesterase type 5 inhibitors and the risk of melanoma skin cancer. Eur Urol 2016; 70: 808.

510. Pottegard A, Schmidt SA, Olesen AB et al: Use of sildenafil or other phosphodiesterase inhibitors and risk of melanoma. Br J Cancer 2016; 115: 895.

511. Matthews A, Langan SM, Douglas IJ et al: Phosphodiesterase type 5 inhibitors and risk of malignant melanoma: matched cohort study using primary care data from the UK clinical practice research datalink. PLoS Med 2016; 13: e1002037.

512. Hill AB: The environment and disease: association or causation? Proc R Soc Med 1965; 58: 295.

513. Michl U, Molfenter F, Graefen M et al: Use of phosphodiesterase type 5 inhibitors may adversely impact biochemical recurrence after radical prostatectomy. J Urol 2015; 193: 479.

514. Gallina A, Bianchi M, Gandaglia G et al: A detailed analysis of the association between postoperative phosphodiesterase type 5 inhibitor use and the risk of biochemical recurrence after radical prostatectomy. Eur Urol 2015; 68: 750.

515. Loeb S, Folkvaljon Y, Robinson D et al: Phosphodiesterase type 5 inhibitor use and disease recurrence after prostate cancer treatment. Eur Urol 2016; 70: 824.

516. Jamnagerwalla J, Howard LE, Vidal AC et al: The association between phosphodiesterase type 5 inhibitors and prostate cancer: results from the REDUCE study. J Urol 2016; 196: 715.

517. Atiemo HO, Szostak MJ and Sklar GN: Salvage of sildenafil failures referred from primary care physicians. J Urol 2003; 170: 2356.

518. Jiann BP, Yu CC, Su CC et al: Rechallenge prior sildenafil nonresponders. Int J Impot Res 2004; 16: 64.

519. Hatzichristou D, Moysidis K, Apostolidis A et al: Sildenafil failures may be due to inadequate patient instructions and follow-up: a study on 100 non-responders. Eur Urol 2005; 47: 518.

520. Gruenwald I, Shenfeld O, Chen J et al: Positive effect of counseling and dose adjustment in patients with erectile dysfunction who failed treatment with sildenafil. Eur Urol 2006; 50: 134.

521. Kim ED, Seftel AD, Goldfischer ER et al: A return to normal erectile function with tadalafil once daily after an incomplete response to as-needed PDE5 inhibitor therapy. J Sex Med 2013; 11: 820.

522. Carson CC, Hatzichristou DG, Carrier S et al: Erectile response with vardenafil in sildenafil nonresponders: a multicentre, double-blind, 12-week, flexible-dose, placebo-controlled erectile dysfunction clinical trial. BJU Int 2004; 94: 1301.

523. Brisson TE, Broderick GA, Thiel DD et al: Vardenafil rescue rates of sildenafil nonresponders: objective assessment of 327 patients with erectile dysfunction. Urology 2006; 68: 397.

524. Ozgur BC, Gonenc F and Yazicioglu AH: Sildenafil or vardenafil nonresponders' erectile response to tadalafil. Urol J 2009; 6: 267.

525. Wespes E, Rammal A and Garbar C: Sildenafil non-responders: haemodynamic and morphometric studies. Eur Urol 2005; 48: 136.

526. Salonia A, Adaikan G, Buvat J et al: Sexual rehabilitation after treatment for prostate cancer-part 2: recommendations from the Fourth International Consultation for Sexual Medicine (ICSM 2015). J Sex Med 2017; 14: 297.

527. Salonia A, Adaikan G, Buvat J et al: Sexual rehabilitation after treatment for prostate cancer-part 1: recommendations from the fourth international consultation for sexual medicine (ICSM 2015). J Sex Med 2017; 14: 285.

528. Sopko NA and Burnett AL: Erection rehabilitation following prostatectomy - current strategies and future directions. Nat Rev Urol 2016; 13: 216.

529. Basal S, Wambi C, Acikel C et al: Optimal strategy for penile rehabilitation after robot-assisted radical prostatectomy based on preoperative erectile function. BJU Int 2013; 111: 658.

530. Fode M, Serefoglu EC, Albersen M et al: Sexuality following radical prostatectomy: is restoration of erectile function enough? Sex Med Rev 2017; 5: 110.

531. Walz J, Epstein JI, Ganzer R et al: A critical analysis of the current knowledge of surgical anatomy of the prostate related to optimisation of cancer control and preservation of continence and erection in candidates for radical prostatectomy: an update. Eur Urol 2016; 70: 301.

532. Nguyen LN, Head L, Witiuk K et al: The risks and benefits of cavernous neurovascular bundle sparing during radical prostatectomy: a systematic review and meta-analysis. J Urol 2017; 198: 760.

533. Schover LR, Fouladi RT, Warneke CL et al: The use of treatments for erectile dysfunction among survivors of prostate carcinoma. Cancer 2002; 95: 2397.

534. Donovan KA, Walker LM, Wassersug RJ et al: Psychological effects of androgen-deprivation therapy on men with prostate cancer and their partners. Cancer 2015; 121: 4286.

535. Nelson CJ and Kenowitz J: Communication and intimacy-enhancing interventions for men diagnosed with prostate cancer and their partners. J Sex Med 2013; 10 Suppl 1: 127.

536. Tal R, Alphs HH, Krebs P et al: Erectile function recovery rate after radical prostatectomy: a meta-analysis. J Sex Med 2009; 6: 2538.

537. al-Abany M, Steineck G, Agren Cronqvist AK et al: Improving the preservation of erectile function after external beam radiation therapy for prostate cancer. Radiother Oncol 2000; 57: 201.

538. van der Wielen GJ, van Putten WL and Incrocci L: Sexual function after three-dimensional conformal radiotherapy for prostate cancer: results from a dose-escalation trial. Int J Radiat Oncol Biol Phys 2007; 68: 479.

539. Burnett AL, Aus G, Canby-Hagino ED et al: Erectile function outcome reporting after clinically localized prostate cancer treatment. J Urol 2007; 178: 597.

540. Ficarra V, Novara G, Ahlering TE et al: Systematic review and meta-analysis of studies reporting potency rates after robot-assisted radical prostatectomy. Eur Urol 2012; 62: 418.

541. Rabbani F, Schiff J, Piecuch M et al: Time course of recovery of erectile function after radical retropubic prostatectomy: does anyone recover after 2 years? J Sex Med 2010; 7: 3984.

542. Nelson CJ, Scardino PT, Eastham JA et al: Back to baseline: erectile function recovery after radical prostatectomy from the patients' perspective. J Sex Med 2013; 10: 1636.

543. Litwin MS, Flanders SC, Pasta DJ et al: Sexual function and bother after radical prostatectomy or radiation for prostate cancer: multivariate quality-of-life analysis from CaPSURE. Cancer of the Prostate Strategic Urologic Research Endeavor. Urology 1999; 54: 503.

544. Mahmood J, Shamah AA, Creed TM et al: Radiation-induced erectile dysfunction: recent advances and future directions. Adv Radiat Oncol 2016; 1: 161.

545. Mulhall JP, Bella AJ, Briganti A et al: Erectile function rehabilitation in the radical prostatectomy patient. J Sex Med 2010; 7: 1687.

546. Burnett AL and Lue TF: Neuromodulatory therapy to improve erectile function recovery outcomes after pelvic surgery. J Urol 2006; 176: 882.

547. Weyne E, Castiglione F, Van der Aa F et al: Landmarks in erectile function recovery after radical prostatectomy. Nat Rev Urol 2015; 12: 289.

548. Ryu JK, Suh JK and Burnett AL: Research in pharmacotherapy for erectile dysfunction. Transl Androl Urol 2017; 6: 207.

549. Segal RL, Bivalacqua TJ and Burnett AL: Current penile-rehabilitation strategies: clinical evidence. Arab J Urol 2013; 11: 230.

550. Sadovsky R, Basson R, Krychman M et al: Cancer and sexual problems. J Sex Med 2010; 7: 349.

551. Walker LM, Wassersug RJ and Robinson JW: Psychosocial perspectives on sexual recovery after prostate cancer treatment. Nat Rev Urol 2015; 12: 167.

552. Salonia A, Burnett AL, Graefen M et al: Prevention and management of postprostatectomy sexual dysfunctions part 2: recovery and preservation of erectile function, sexual desire, and org*smic function. Eur Urol 2012; 62: 273.

553. Aversa A, Isidori AM, Spera G et al: Androgens improve cavernous vasodilation and response to sildenafil in patients with erectile dysfunction. Clin Endocrinol (Oxf) 2003; 58: 632.

554. Buvat J, Montorsi F, Maggi M et al: Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). J Sex Med 2011; 8: 284.

555. Shabsigh R, Kaufman JM, Steidle C et al: Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol 2004; 172: 658.

556. Spitzer M, Basaria S, Travison TG et al: Effect of testosterone replacement on response to sildenafil citrate in men with erectile dysfunction: a parallel, randomized trial. Ann Intern Med 2012; 157: 681.

557. Shamloul R, Ghanem H, Fahmy I et al: Testosterone therapy can enhance erectile function response to sildenafil in patients with PADAM: a pilot study. J Sex Med 2005; 2: 559.

558. Kalinchenko SY, Kozlov GI, Gontcharov NP et al: Oral testosterone undecanoate reverses erectile dysfunction associated with diabetes mellitus in patients failing on sildenafil citrate therapy alone. Aging Male 2003; 6: 94.

559. Rosenthal BD, May NR, Metro MJ et al: Adjunctive use of Androgel (testosterone gel) with sildenafil to treat erectile dysfunction in men with acquired androgen deficiency syndrome after failure using sildenafil alone. Urology 2006; 67: 571.

560. Yassin AA, Saad F and Diede HE: Testosterone and erectile function in hypogonadal men unresponsive to tadalafil: results from an open-label uncontrolled study. Andrologia 2006; 38: 61. 561. Hwang TI, Chen HE, Tsai TF et al: Combined use of androgen and sildenafil for hypogonadal patients unresponsive to sildenafil alone. Int J Impot Res 2006; 18: 400.

562. Kim JW, Oh MM, Park MG et al: Combination therapy of testosterone enanthate and tadalafil on PDE5 inhibitor non-reponders with severe and intermediate testosterone deficiency. Int J Impot Res 2013; 25: 29.

563. Alhathal N, Elshal AM and Carrier S: Synergetic effect of testosterone and phophodiesterase-5 inhibitors in hypogonadal men with erectile dysfunction: a systematic review. Can Urol Assoc J 2012; 6: 269.

564. Corona G, Isidori AM, Buvat J et al: Testosterone supplementation and sexual function: a meta-analysis study. J Sex Med 2014; 11: 1577.

565. Bolona ER, Uraga MV, Haddad RM et al: Testosterone use in men with sexual dysfunction: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc 2007; 82: 20.

566. Huo S, Scialli AR, McGarvey S et al: Treatment of men for "low testosterone:" a systematic review. PLoS One 2016; 11: e0162480.

567. Algeffari M, Jayasena CN, MacKeith P et al: Testosterone therapy for sexual dysfunction in men with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabet Med 2018; 35: 195.

568. al-Juburi AZ and O'Donnell PD: Synergist erection system: clinical experience. Urology 1990; 35: 304.

569. Aloui R, Iwaz J, Kokkidis MJ et al: A new vacuum device as alternative treatment for impotence. Br J Urol 1992; 70: 652.

570. Asopa R and Williams G: Use of the "correctaid" device in the management of impotence. Br J Urol 1989; 63: 546.

571. Baltaci S, Aydos K, Kosar A et al: Treating erectile dysfunction with a vacuum tumescence device: a retrospective analysis of acceptance and satisfaction. Br J Urol 1995; 76: 757.

572. Blackard CE, Borkon WD, Lima JS et al: Use of vacuum tumescence device for impotence secondary to venous leakage. Urology 1993; 41: 225.

573. Bosshardt RJ, Farwerk R, Sikora R et al: Objective measurement of the effectiveness, therapeutic success and dynamic mechanisms of the vacuum device. Br J Urol 1995; 75: 786.

574. Broderick GA, Allen G and McClure RD: Vacuum tumescence devices: the role of papaverine in the selection of patients. J Urol 1991; 145: 284.

575. Cookson MS and Nadig PW: Long-term results with vacuum constriction device. J Urol 1993; 149: 290.

576. Derouet H, Caspari D, Rohde V et al: Treatment of erectile dysfunction with external vacuum devices. Andrologia 1999; 31 Suppl 1: 89.

577. Dutta TC and Eid JF: Vacuum constriction devices for erectile dysfunction: a long-term, prospective study of patients with mild, moderate, and severe dysfunction. Urology 1999; 54: 891.

578. Earle CM, Seah M, Coulden SE et al: The use of the vacuum erection device in the management of erectile impotence. Int J Impot Res 1996; 8: 237.

579. el-Bahrawy M, el-Baz MA, Emam A et al: Noninvasive vacuum constriction device in the management of erectile dysfunction. Int Urol Nephrol 1995; 27: 331.

580. Gilbert HW and Gingell JC: Vacuum constriction devices: second-line conservative treatment for impotence. Br J Urol 1992; 70: 81. 581. Gould JE, Switters DM, Broderick GA et al: External vacuum devices: a clinical comparison with pharmacologic erections. World J Urol 1992; 10: 68.

582. Kaplan FJ, Levitt NS, Stevens PJ et al: Non-invasive management of organic impotence. S Afr Med J 1995; 85: 276.

583. Khayyamfar F, Forootan SK, Ghasemi H et al: Evaluating the efficacy of vacuum constrictive device and causes of its failure in impotent patients. Urol J 2013; 10: 1072.

584. Kolettis PN, Lakin MM, Montague DK et al: Efficacy of the vacuum constriction device in patients with corporeal venous occlusive dysfunction. Urology 1995; 46: 856.

585. Korenman SG and Viosca SP: Use of a vacuum tumescence device in the management of impotence in men with a history of penile implant or severe pelvic disease. J Am Geriatr Soc 1992; 40: 61.

586. Korenman SG, Viosca SP, Kaiser FE et al: Use of a vacuum tumescence device in the management of impotence. J Am Geriatr Soc 1990; 38: 217.

587. Lewis RW and Witherington R: External vacuum therapy for erectile dysfunction: use and results. World J Urol 1997; 15: 78.

588. Meinhardt W, Lycklama a Nijeholt AA, Kropman RF et al: The negative pressure device for erectile disorders: when does it fail? J Urol 1993; 149: 1285.

589. Moul JW and McLeod DG: Negative pressure devices in the explanted penile prosthesis population. J Urol 1989; 142: 729.

590. Nadig PW, Ware JC and Blumoff R: Noninvasive device to produce and maintain an erection-like state. Urology 1986; 27: 126.

591. Opsomer RJ, Wese FX, De Groote P et al: The external vacuum device in the management of erectile dysfunction. Acta Urol Belg 1997; 65: 13.

592. Segenreich E, Israilov SR, Shmueli J et al: Vacuum therapy combined with psychotherapy for management of severe erectile dysfunction. Eur Urol 1995; 28: 47.

593. Sidi AA, Becher EF, Zhang G et al: Patient acceptance of and satisfaction with an external negative pressure device for impotence. J Urol 1990; 144: 1154.

594. Sidi AA and Lewis JH: Clinical trial of a simplified vacuum erection device for impotence treatment. Urology 1992; 39: 526.

595. Turner LA, Althof SE, Levine SB et al: External vacuum devices in the treatment of erectile dysfunction: a one-year study of sexual and psychosocial impact. J Sex Marital Ther 1991; 17: 81.

596. Turner LA, Althof SE, Levine SB et al: Treating erectile dysfunction with external vacuum devices: impact upon sexual, psychological and marital functioning. J Urol 1990; 144: 79.

597. van Thillo EL and Delaere KP: The vacuum erection device. A noninvasive treatment for impotence. Acta Urol Belg 1992; 60: 9.

598. Villeneuve R, Corcos J and Carmel M: Assisted erection follow-up with couples. J Sex Marital Ther 1991; 17: 94.

599. Vrijhof HJ and Delaere KP: Vacuum constriction devices in erectile dysfunction: acceptance and effectiveness in patients with impotence of organic or mixed aetiology. Br J Urol 1994; 74: 102.

600. Willard BA: An assessment of a vacuum constriction device in treating erectile dysfunction. Urol Nurs 1998; 18: 33.

601. Witherington R: Vacuum constriction device for management of erectile impotence. J Urol 1989; 141: 320.

602. Arauz-Pacheco C, Basco M, Ramirez LC et al: Treatment of diabetic impotence with a vacuum device: efficacy and effects on psychological status. Am J Med Sci 1992; 303: 281.

603. Bodansky HJ: Treatment of male erectile dysfunction using the active vacuum assist device. Diabet Med 1994; 11: 410.

604. Famuyiwa OO, Al-Jasser SJ, Ahmad AS et al: Experience with the vacuum-enhanced tumescence erecaid system in the treatment of erectile impotence among diabetic patients in Saudi Arabia. Practical Diabetes 1992; 9: 141.

605. Israilov S, Shmuely J, Niv E et al: Evaluation of a progressive treatment program for erectile dysfunction in patients with diabetes mellitus. Int J Impot Res 2005; 17: 431.

606. Pajovic B, Dimitrovski A, Fatic N et al: Vacuum erection device in treatment of organic erectile dysfunction and penile vascular differences between patients with DM type I and DM type II. Aging Male 2017; 20: 49.

607. Price DE, Cooksey G, Jehu D et al: The management of impotence in diabetic men by vacuum tumescence therapy. Diabet Med 1991; 8: 964.

608. Sun L, Peng FL, Yu ZL et al: Combined sildenafil with vacuum erection device therapy in the management of diabetic men with erectile dysfunction after failure of first-line sildenafil monotherapy. Int J Urol 2014; 21: 1263.

609. Engel JD: Effect on sexual function of a vacuum erection device post-prostatectomy. Can J Urol 2011; 18: 5721.

610. Nason GJ, McNamara F, Twyford M et al: Efficacy of vacuum erectile devices (VEDs) after radical prostatectomy: the initial Irish experience of a dedicated VED clinic. Int J Impot Res 2016; 6: 205.

611. Raina R, Agarwal A, Ausmundson S et al: Early use of vacuum constriction device following radical prostatectomy facilitates early sexual activity and potentially earlier return of erectile function. Int J Impot Res 2006; 18: 77.

612. Denil J, Ohl DA and Smythe C: Vacuum erection device in spinal cord injured men: patient and partner satisfaction. Arch Phys Med Rehabil 1996; 77: 750.

613. Heller L, Aloni R, Keren O et al: Vacuum tumescence constriction therapy for neuropathic impotence. Int J Adolesc Med Health 1994; 7: 255.

614. Lloyd EE, Toth LL and Perkash I: Vacuum tumescence: an option for spinal cord injured males with erectile dysfunction. SCI Nurs 1989; 6: 25. 615. Seckin B, Atmaca I, Ozgok Y et al: External vacuum device therapy for spinal cord injured males with erectile dysfunction. Int Urol Nephrol 1996; 28: 235.

616. Watanabe T, Chancellor MB, Rivas DA et al: Epidemiology of current treatment for sexual dysfunction in spinal cord injured men in the USA model spinal cord injury centers. J Spinal Cord Med 1996; 19: 186.

617. Zasler ND and Katz PG: Synergist erection system in the management of impotence secondary to spinal cord injury. Arch Phys Med Rehabil 1989; 70: 712.

618. Chen J, Mabjeesh NJ and Greenstein A: Sildenafil versus the vacuum erection device: patient preference. J Urol 2001; 166: 1779.

619. Canguven O, Bailen J, Fredriksson W et al: Combination of vacuum erection device and PDE5 inhibitors as salvage therapy in PDE5 inhibitor nonresponders with erectile dysfunction. J Sex Med 2009; 6: 2561.

620. Kohler TS, Pedro R, Hendlin K et al: A pilot study on the early use of the vacuum erection device after radical retropubic prostatectomy. BJU Int 2007; 100: 858.

621. Brison D, Seftel A and Sadeghi-Nejad H: The resurgence of the vacuum erection device (VED) for treatment of erectile dysfunction. J Sex Med 2013; 10: 1124.

622. Padma-Nathan H, Hellstrom WJ, Kaiser FE et al: Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated Urethral System for Erection (MUSE) Study Group. N Engl J Med 1997; 336: 1.

623. Williams G, Abbou CC, Amar ET et al: Efficacy and safety of transurethral alprostadil therapy in men with erectile dysfunction. MUSE Study Group. Br J Urol 1998; 81: 889.

624. Shokeir AA, Alserafi MA and Mutabagani H: Intracavernosal versus intraurethral alprostadil: a prospective randomized study. BJU Int 1999; 83: 812.

625. Shabsigh R, Padma-Nathan H, Gittleman M et al: Intracavernous alprostadil alfadex is more efficacious, better tolerated, and preferred over intraurethral alprostadil plus optional actis: a comparative, randomized, crossover, multicenter study. Urology 2000; 55: 109.

626. Chiang HS, Wen TC and Liang JF: Titration study of MUSE (Medicated Urethral System for Erection) in erectile dysfunction. J Formos Med Assoc 2000; 99: 926.

627. Ekman P, Sjogren L, Englund G et al: Optimizing the therapeutic approach of transurethral alprostadil. BJU Int 2000; 86: 68.

628. Guay AT, Perez JB, Velasquez E et al: Clinical experience with intraurethral alprostadil (MUSE) in the treatment of men with erectile dysfunction. A retrospective study. Medicated urethral system for erection. Eur Urol 2000; 38: 671.

629. Jaffe JS, Antell MR, Greenstein M et al: Use of intraurethral alprostadil in patients not responding to sildenafil citrate. Urology 2004; 63: 951.

630. Khan MA, Raistrick M, Mikhailidis DP et al: MUSE: clinical experience. Curr Med Res Opin 2002; 18: 64.

631. Kim SC, Ahn TY, Choi HK et al: Multicenter study of the treatment of erectile dysfunction with transurethral alprostadil (MUSE) in Korea. Int J Impot Res 2000; 12: 97.

632. Kongkanand A, Ratana-Olarn K, Wuddhikarn S et al: Evaluation of transurethal alprostadil for safety and efficacy in men with erectile dysfunction. J Med Assoc Thai 2002; 85: 223.

633. Mulhall JP, Jahoda AE, Ahmed A et al: Analysis of the consistency of intraurethral prostaglandin E1 (MUSE) during at-home use. Urology 2001; 58: 262.

634. Garrido Abad P, Sinues Ojas B, Martinez Blazquez L et al: Safety and efficacy of intraurethral alprostadil in patients with erectile dysfunction refractory to treatment using phosphodiesterase-5 inhibitors. Actas Urol Esp 2015; 39: 635.

635. Pangkahila WI: Evaluation of transurethral application of alprostadil for erectile dysfunction in Indonesians. Asian J Androl 2000; 2: 233.

636. Shabsigh R, Padma-Nathan H, Gittleman M et al: Intracavernous alprostadil alfadex (EDEX/VIRIDAL) is effective and safe in patients with erectile dysfunction after failing sildenafil (Viagra). Urology 2000; 55: 477.

637. Hatzichristou DG, Apostolidis A, Tzortzis V et al: Sildenafil versus intracavernous injection therapy: efficacy and preference in patients on intracavernous injection for more than 1 year. J Urol 2000; 164: 1197.

638. al-Juburi AZ and O'Donnell PD: Follow up outcome of intracavernous papaverine. J Ark Med Soc 1990; 86: 383.

639. Alexandre B, Lemaire A, Desvaux P et al: Intracavernous injections of prostaglandin E1 for erectile dysfunction: patient satisfaction and quality of sex life on long-term treatment. J Sex Med 2007; 4: 426.

640. Althof SE, Turner LA, Levine SB et al: Intracavernosal injection in the treatment of impotence: a prospective study of sexual, psychological, and marital functioning. J Sex Marital Ther 1987; 13: 155.

641. Althof SE, Turner LA, Levine SB et al: Sexual, psychological, and marital impact of self-injection of papaverine and phentolamine: a long-term prospective study. J Sex Marital Ther 1991; 17: 101.

642. Armstrong DK, Convery A and Dinsmore WW: Intracavernosal papaverine and phentolamine for the medical management of erectile dysfunction in a genitourinary clinic. Int J STD AIDS 1993; 4: 214.

643. Armstrong DK, Convery A and Dinsmore WW: Prostaglandin E1 in the medical management of erectile dysfunction in a genito-urinary medicine clinic. Ulster Med J 1994; 63: 18.

644. Armstrong DK, Convery AG and Dinsmore WW: Reasons for patient drop-out from an intracavernous auto-injection programme for erectile dysfunction. Br J Urol 1994; 74: 99.

645. Bahren W, Scherb W, Gall H et al: Effects of intracavernosal pharmacotherapy on self-esteem, performance anxiety and partnership in patients with chronic erectile dysfunction. Eur Urol 1989; 16: 175.

646. Baniel J, Israilov S, Engelstein D et al: Three-year outcome of a progressive treatment program for erectile dysfunction with intracavernous injections of vasoactive drugs. Urology 2000; 56: 647.

647. Baum N, Randrup E, Junot D et al: Prostaglandin E1 versus sex therapy in the management of psychogenic erectile dysfunction. Int J Impot Res 2000; 12: 191.

648. Bennett AH, Carpenter AJ and Barada JH: An improved vasoactive drug combination for a pharmacological erection program. J Urol 1991; 146: 1564.

649. Beretta G, Zanollo A, Ascani L et al: Prostaglandin E1 in the therapy of erectile deficiency. Acta Eur Fertil 1989; 20: 305.

650. Brindley GS: Maintenance treatment of erectile impotence by cavernosal unstriated muscle relaxant injection. Br J Psychiatry 1986; 149: 210.

651. Brock G, Tu LM and Linet OI: Return of spontaneous erection during long-term intracavernosal alprostadil (CAVERJECT) treatment. Urology 2001; 57: 536.

652. Brown SL, Haas CA, Koehler M et al: Hepatotoxicity related to intracavernous pharmacotherapy with papaverine. Urology 1998; 52: 844.

653. Buvat J, Costa P, Morlier D et al: Double-blind multicenter study comparing alprostadil alpha-cyclodextrin with moxisylyte chlorhydrate in patients with chronic erectile dysfunction. J Urol 1998; 159: 116.

654. Buvat J, Lemaire A and Herbaut-Buvat M: Intracavernous pharmacotherapy: comparison of moxisylyte and prostaglandin E1. Int J Impot Res 1996; 8: 41.

655. Canale D, Giorgi PM, Lencioni R et al: Long-term intracavernous self-injection with prostaglandin E1 for the treatment of erectile dysfunction. Int J Androl 1996; 19: 28.

656. Casabe A, Bechara A, Cheliz G et al: Drop-out reasons and complications in self-injection therapy with a triple vasoactive drug mixture in sexual erectile dysfunction. Int J Impot Res 1998; 10: 5.

657. Chen J, Godschalk M, Katz PG et al: The lowest effective dose of prostaglandin E1 as treatment for erectile dysfunction. J Urol 1995; 153: 80.

658. Chen J, Godschalk MF, Katz PG et al: Incidence of penile pain after injection of a new formulation of prostaglandin E1. J Urol 1995; 154: 77.

659. Chen RN, Lakin MM, Montague DK et al: Penile scarring with intracavernous injection therapy using prostaglandin E1: a risk factor analysis. J Urol 1996; 155: 138.

660. Chew KK, Stuckey BG, Earle CM et al: Penile fibrosis in intracavernosal prostaglandin E1 injection therapy for erectile dysfunction. Int J Impot Res 1997; 9: 225.

661. Chiang HS, Wen TC, Wu CC et al: Intracavernous self-injection therapy for the treatment of erectile dysfunction. J Formos Med Assoc 1992; 91: 898.

662. Coombs PG, Heck M, Guhring P et al: A review of outcomes of an intracavernosal injection therapy programme. BJU Int 2012; 110: 1787.

663. Cooper AJ: Evaluation of I-C papaverine in patients with psychogenic and organic impotence. Can J Psychiatry 1991; 36: 574.

664. de la Taille A, Delmas V, Amar E et al: Reasons of dropout from short- and long-term self-injection therapy for impotence. Eur Urol 1999; 35: 312.

665. Dhabuwala CB, Kerkar P, Bhutwala A et al: Intracavernous papaverine in the management of psychogenic impotence. Arch Androl 1990; 24: 185.

666. Dinsmore WW: Medical treatment of impotence with papaverine and phentolamine intracavernosal injection. Ulster Med J 1990; 59: 174.

667. Dinsmore WW, Gingell C, Hackett G et al: Treating men with predominantly nonpsychogenic erectile dysfunction with intracavernosal vasoactive intestinal polypeptide and phentolamine mesylate in a novel auto-injector system: a multicentre double-blind placebo-controlled study. BJU Int 1999; 83: 274.

668. El-Sakka AI: Intracavernosal prostaglandin E1 self vs office injection therapy in patients with erectile dysfunction. Int J Impot Res 2006; 18: 180.

669. The long-term safety of alprostadil (prostaglandin-E1) in patients with erectile dysfunction. The European Alprostadil Study Group. Br J Urol 1998; 82: 538.

670. Flynn RJ and Williams G: Long-term follow-up of patients with erectile dysfunction commenced on self injection with intracavernosal papaverine with or without phentolamine. Br J Urol 1996; 78: 628.

671. Gall H, Sparwasser C, Bahren W et al: Long-term results of corpus cavernosum autoinjection therapy for chronic erectile dysfunction. Andrologia 1992; 24: 285.

672. Gerber GS and Levine LA: Pharmacological erection program using prostaglandin E1. J Urol 1991; 146: 786.

673. Gerstenberg TC, Metz P, Ottesen B et al: Intracavernous self-injection with vasoactive intestinal polypeptide and phentolamine in the management of erectile failure. J Urol 1992; 147: 1277.

674. Girdley FM, Bruskewitz RC, Feyzi J et al: Intracavernous self-injection for impotence: a long-term therapeutic option? Experience in 78 patients. J Urol 1988; 140: 972.

675. Godschalk M, Gheorghiu D, Chen J et al: Long-term efficacy of a new formulation of prostaglandin E1 as treatment for erectile failure. J Urol 1996; 155: 915.

676. Godschalk MF, Chen J, Katz PG et al: Prostaglandin E1 as treatment for erectile failure in elderly men. J Am Geriatr Soc 1994; 42: 1263.

677. Godschalk MF, Chen J, Katz PG et al: Treatment of erectile failure with prostaglandin E1: a double-blind, placebo-controlled, dose-response study. J Urol 1994; 151: 1530.

678. Govier FE, McClure RD, Weissman RM et al: Experience with triple-drug therapy in a pharmacological erection program. J Urol 1993; 150: 1822.

679. Gupta R, Kirschen J, Barrow RC et al: Predictors of success and risk factors for attrition in the use of intracavernous injection. J Urol 1997; 157: 1681.

680. Hattat H, Ozkara H, Akkus E et al: Our experience with pharmacological erection treatment of erectile dysfunction. J Androl 1994; 15 Suppl: 47s.

681. Hauck EW, Altinkilic BM, Schroeder-Printzen I et al: Prostaglandin E1 long-term self-injection programme for treatment of erectile dysfunction--a follow-up of at least 5 years. Andrologia 1999; 31 Suppl 1: 99.

682. He L, Wen J, Jiang X et al: Long-term efficacy and safety of self-intracavernous injection of prostaglandin E1 for treatment of erectile dysfunction in China. Andrologia 2011; 43: 208.

683. Hirsch IH, Schanne FJ, Carsello J et al: Sequential penile ultrasound monitoring of patients treated with chronic intracavernous prostaglandin E1. Urology 1995; 45: 1037.

684. Hollander JB, Gonzalez J and Norman T: Patient satisfaction with pharmacologic erection program. Urology 1992; 39: 439.

685. Hsiao W, Bennett N, Guhring P et al: Satisfaction profiles in men using intracavernosal injection therapy. J Sex Med 2011; 8: 512.

686. Irwin MB and Kata EJ: High attrition rate with intracavernous injection of prostaglandin E1 for impotency. Urology 1994; 43: 84.

687. Ismail M, Abbott L and Hirsch IH: Experience with intracavernous PGE-1 in the treatment of erectile dysfunction: dose considerations and efficacy. Int J Impot Res 1997; 9: 39.

688. Janosko EO: Intracavernous self-injection of papaverine and regitine for the treatment of organic impotence. N C Med J 1986; 47: 305.

689. Kaplan SA, Reis RB, Kohn IJ et al: Combination therapy using oral alpha-blockers and intracavernosal injection in men with erectile dysfunction. Urology 1998; 52: 739.

690. Kerfoot WW and Carson CC: Pharmacologically induced erections among geriatric men. J Urol 1991; 146: 1022.

691. Khan MM and Khwaja M: Open label study of intracavernous injection of alpostadil alphadex in the treatment of erectile dysfunction. Journal of Postgraduate Medical Institute 2005; 19: 52.

692. Kirkeby HJ and Johannesen NL: Pharmacologically induced prolonged erections produced by papaverine. Follow-up of injection therapy. Scand J Urol Nephrol Suppl 1989; 125: 97.

693. Kunelius P and Lukkarinen O: Intracavernous self-injection of prostaglandin E1 in the treatment of erectile dysfunction. Int J Impot Res 1999; 11: 21.

694. Lakin MM, Montague DK, VanderBrug Medendorp S et al: Intracavernous injection therapy: analysis of results and complications. J Urol 1990; 143: 1138.

695. Lehmann K, Casella R, Blochlinger A et al: Reasons for discontinuing intracavernous injection therapy with prostaglandin E1 (alprostadil). Urology 1999; 53: 397.

696. Levine SB, Althof SE, Turner LA et al: Side effects of self-administration of intracavernous papaverine and phentolamine for the treatment of impotence. J Urol 1989; 141: 54.

697. Linet OI and Ogrinc FG: Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study Group. N Engl J Med 1996; 334: 873.

698. Willke RJ, Glick HA, McCarron TJ et al: Quality of life effects of alprostadil therapy for erectile dysfunction. J Urol 1997; 157: 2124.

699. Lloyd LK and Richards JS: Intracavernous pharmacotherapy for management of erectile dysfunction in spinal cord injury. Paraplegia 1989; 27: 457.

700. Lundberg L, Olsson JO and Kihl B: Long-term experience of self-injection therapy with prostaglandin E1 for erectile dysfunction. Scand J Urol Nephrol 1996; 30: 395.

701. Meinhardt W, de la Fuente RB, Lycklama a Nijeholt AA et al: Prostaglandin E1 with phentolamine for the treatment of erectile dysfunction. Int J Impot Res 1996; 8: 5.

702. Meinhardt W, Lycklama a Nijeholt AA, Kropman RF et al: Comparison of a mixture of papaverine, phentolamine and prostaglandin E1 with other intracavernous injections. Eur Urol 1994; 26: 319.

703. Moemen MN, Hamed HA, Kamel, II et al: Clinical and sonographic assessment of the side effects of intracavernous injection of vasoactive substances. Int J Impot Res 2004; 16: 143.

704. Montorsi F, Guazzoni G, Bergamaschi F et al: Effectiveness and safety of multidrug intracavernous therapy for vasculogenic impotence. Urology 1993; 42: 554.

705. Montorsi F, Guazzoni G, Bergamaschi F et al: Four-drug intracavernous therapy for impotence due to corporeal veno-occlusive dysfunction. J Urol 1993; 149: 1291.

706. Mulhall JP, Jahoda AE, Cairney M et al: The causes of patient dropout from penile self-injection therapy for impotence. J Urol 1999; 162: 1291.

707. Nellans RE, Ellis LR and Kramer-Levien D: Pharmacological erection: diagnosis and treatment applications in 69 patients. J Urol 1987; 138: 52.

708. Nelson RP: Injections of papaverine and regitine into the corpora cavernosa for erectile dysfunction: clinical results in 60 patients. South Med J 1989; 82: 26.

709. Nisen H: Cavernous auto-injection therapy with prostaglandin E1. Ann Chir Gynaecol Suppl 1993; 206: 69.

710. Pagliarulo A, Ludovico GM, Cirillo-Marucco E et al: Compliance to longterm vasoactive intracavernous therapy. Int J Impot Res 1996; 8: 63.

711. Perimenis P, Athanasopoulos A, Geramoutsos I et al: The incidence of pharmacologically induced priapism in the diagnostic and therapeutic management of 685 men with erectile dysfunction. Urol Int 2001; 66: 27.

712. Perimenis P, Gyftopoulos K, Athanasopoulos A et al: Diabetic impotence treated by intracavernosal injections: high treatment compliance and increasing dosage of vaso-active drugs. Eur Urol 2001; 40: 398.

713. Pery M, Rosenberger A, Kaftori JK et al: Intracorporeal calcifications after self-injection of papaverine. Radiology 1990; 176: 81.

714. Porst H, Buvat J, Meuleman E et al: Intracavernous alprostadil alfadex--an effective and well tolerated treatment for erectile dysfunction. Results of a long-term European study. Int J Impot Res 1998; 10: 225.

715. Porst H, van Ahlen H, Block T et al: Intracavernous self-injection of prostaglandin E1 in the therapy of erectile dysfunction. Vasa Suppl 1989; 28: 50.

716. Puppo P, De Rose AF, Pittaluga P et al: Diagnosis of male impotence after intracavernous papaverine test. Eur Urol 1988; 15: 213.

717. Purvis K, Egdetveit I and Christiansen E: Intracavernosal therapy for erectile failure--impact of treatment and reasons for drop-out and dissatisfaction. Int J Impot Res 1999; 11: 287.

718. Rabbani KJ, Tauqeer F and Rabbani R: Prostaglandin E1 for the medical management of erectile dysfunction. Pak J Med Health Sci 2010; 4: 512.

719. Robinette MA and Moffat MJ: Intracorporal injection of papaverine and phentolamine in the management of impotence. Br J Urol 1986; 58: 692.

720. Robinson PK: An observational study of prostaglandin E1: comparing trial and maintenance dose. Urol Nurs 1994; 14: 76.

721. Rowland DL, Boedhoe HS, Dohle G et al: Intracavernosal self-injection therapy in men with erectile dysfunction: satisfaction and attrition in 119 patients. Int J Impot Res 1999; 11: 145.

722. Ruutu M, Lindstrom BL, Virtanen J et al: Intracavernous self-injection for erectile failure. Eur Urol 1988; 15: 96.

723. Sandhu D, Curless E, Dean J et al: A double blind, placebo controlled study of intracavernosal vasoactive intestinal polypeptide and phenotolamine mesylate in a novel auto-injector for the treatment of non-psychogenic erectile dysfunction. Int J Impot Res 1999; 11: 91.

724. Schramek P, Dorninger R, Waldhauser M et al: Prostaglandin E1 in erectile dysfunction. Efficiency and incidence of priapism. Br J Urol 1990; 65: 68.

725. Sexton WJ, Benedict JF and Jarow JP: Comparison of long-term outcomes of penile prostheses and intracavernosal injection therapy. J Urol 1998; 159: 811.

726. Shah PJ, Dinsmore W, Oakes RA et al: Injection therapy for the treatment of erectile dysfunction: a comparison between alprostadil and a combination of vasoactive intestinal polypeptide and phentolamine mesilate. Curr Med Res Opin 2007; 23: 2577.

727. Sidi AA, Reddy PK and Chen KK: Patient acceptance of and satisfaction with vasoactive intracavernous pharmacotherapy for impotence. J Urol 1988; 140: 293.

728. Soderdahl DW, Thrasher JB and Hansberry KL: Intracavernosal drug-induced erection therapy versus external vacuum devices in the treatment of erectile dysfunction. Br J Urol 1997; 79: 952.

729. Sparwasser C, Drescher P, Pust RA et al: Long-term results of therapy with intracavernousal injections and penile venous surgery in chronic erectile dysfunction. Scand J Urol Nephrol Suppl 1994; 157: 107.

730. Stackl W, Hasun R and Marberger M: Intracavernous injection of prostaglandin E1 in impotent men. J Urol 1988; 140: 66.

731. Stief CG, Gall H, Scherb W et al: Mid-term results of autoinjection therapy for erectile dysfunction. Urology 1988; 31: 483.

732. Sundaram CP, Thomas W, Pryor LE et al: Long-term follow-up of patients receiving injection therapy for erectile dysfunction. Urology 1997; 49: 932.

733. Sung HH, Ahn JS, Kim JJ et al: The role of intracavernosal injection therapy and the reasons of withdrawal from therapy in patients with erectile dysfunction in the era of PDE5 inhibitors. Andrology 2014; 2: 45.

734. Torok A, Szekely J and Gotz F: Papaverine-induced erection. Int Urol Nephrol 1989; 21: 195.

735. Turner LA, Althof SE, Levine SB et al: Twelve-month comparison of two treatments for erectile dysfunction: self-injection versus external vacuum devices. Urology 1992; 39: 139.

736. Turner LA, Althof SE, Levine SB et al: Self-injection of papaverine and phentolamine in the treatment of psychogenic impotence. J Sex Marital Ther 1989; 15: 163.

737. Valdevenito R and Melman A: Intracavernous self-injection pharmacotherapy program: analysis of results and complications. Int J Impot Res 1994; 6: 81.

738. van der Windt F, Dohle GR, van der Tak J et al: Intracavernosal injection therapy with and without sexological counselling in men with erectile dysfunction. BJU Int 2002; 89: 901.

739. Virag R, Shoukry K, Floresco J et al: Intracavernous self-injection of vasoactive drugs in the treatment of impotence: 8-year experience with 615 cases. J Urol 1991; 145: 287.

740. Watters GR, Keogh EJ, Earle CM et al: Experience in the management of erectile dysfunction using the intracavernosal self-injection of vasoactive drugs. J Urol 1988; 140: 1417.

741. Weidner W, Schroeder-Printzen I, Fischer C et al: Experience in the treatment of erectile dysfunction using the intracavernosal self-injection of papaverine: results of a prospective study after a median follow-up of 42 months involving 135 patients and 10766 injections. World J Urol 1992; 10: 179.

742. Weiss JN, Badlani GH, Ravalli R et al: Reasons for high drop-out rate with self-injection therapy for impotence. Int J Impot Res 1994; 6: 171.

743. Williams G, Mulcahy MJ and Kiely EA: Impotence: treatment by autoinjection of vasoactive drugs. Br Med J (Clin Res Ed) 1987; 295: 595.

744. Wu CC, Xue ZY, Apichat K et al: The use of alprostadil sterile powder in a home self-injection study of Asian men with erectile dysfunction. Clin Ther 1996; 18: 256.

745. Bell DS, Cutter GR, Hayne VB et al: Factors predicting efficacy of phentolamine-papaverine intracorporeal injection for treatment of erectile dysfunction in diabetic male. Urology 1992; 40: 36.

746. Heaton JP, Lording D, Liu SN et al: Intracavernosal alprostadil is effective for the treatment of erectile dysfunction in diabetic men. Int J Impot Res 2001; 13: 317.

747. Montorsi F, Guazzoni G, Bergamaschi F et al: Clinical reliability of multi-drug intracavernous vasoactive pharmacotherapy for diabetic impotence. Acta Diabetol 1994; 31: 1.

748. Perimenis P, Konstantinopoulos A, Perimeni PP et al: Long-term treatment with intracavernosal injections in diabetic men with erectile dysfunction. Asian J Androl 2006; 8: 219.

749. Tsai YS, Lin JS and Lin YM: Safety and efficacy of alprostadil sterile powder (s. Po., CAVERJECT) in diabetic patients with erectile dysfunction. Eur Urol 2000; 38: 177.

750. Israilov S, Niv E, Livne PM et al: Intracavernous injections for erectile dysfunction in patients with cardiovascular diseases and failure or contraindications for sildenafil citrate. Int J Impot Res 2002; 14: 38.

751. Albaugh JA and Ferrans CE: Impact of penile injections on men with erectile dysfunction after prostatectomy. Urol Nurs 2010; 30: 64.

752. Claro Jde A, de Aboim JE, Maringolo M et al: Intracavernous injection in the treatment of erectile dysfunction after radical prostatectomy: an observational study. Sao Paulo Med J 2001; 119: 135.

753. Dennis RL and McDougal WS: Pharmacological treatment of erectile dysfunction after radical prostatectomy. J Urol 1988; 139: 775.

754. Domes T, Chung E, DeYoung L et al: Clinical outcomes of intracavernosal injection in postprostatectomy patients: a single-center experience. Urology 2012; 79: 150.

755. Gontero P, Fontana F, Bagnasacco A et al: Is there an optimal time for intracavernous prostaglandin E1 rehabilitation following nonnerve sparing radical prostatectomy? Results from a hemodynamic prospective study. J Urol 2003; 169: 2166.

756. Montorsi F, Guazzoni G, Strambi LF et al: Recovery of spontaneous erectile function after nerve-sparing radical retropubic prostatectomy with and without early intracavernous injections of alprostadil: results of a prospective, randomized trial. J Urol 1997; 158: 1408.

757. Mydlo JH, Viterbo R and Crispen P: Use of combined intracorporal injection and a phosphodiesterase-5 inhibitor therapy for men with a suboptimal response to sildenafil and/or vardenafil monotherapy after radical retropubic prostatectomy. BJU Int 2005; 95: 843.

758. Prabhu V, Alukal JP, Laze J et al: Long-term satisfaction and predictors of use of intracorporeal injections for post-prostatectomy erectile dysfunction. J Urol 2013; 189: 238.

759. Raina R, Lakin MM, Thukral M et al: Long-term efficacy and compliance of intracorporeal (IC) injection for erectile dysfunction following radical prostatectomy: SHIM (IIEF-5) analysis. Int J Impot Res 2003; 15: 318.

760. Yiou R, Bütow Z, Parisot J et al: Is it worth continuing sexual rehabilitation after radical prostatectomy with intracavernous injection of alprostadil for more than 1 year? Sex Med 2015; 3: 42.

761. Yiou R, Cunin P, de la Taille A et al: Sexual rehabilitation and penile pain associated with intracavernous alprostadil after radical prostatectomy. J Sex Med 2011; 8: 575.

762. Mansi MK, Alkhudair WK and Huraib S: Treatment of erectile dysfunction after kidney transplantation with intracavernosal self-injection of prostaglandin E1. J Urol 1998; 159: 1927.

763. Beretta G, Zanollo A, Fanciullacci F et al: Intracavernous injection of papaverine in paraplegic males. Acta Eur Fertil 1986; 17: 283.

764. Bodner DR, Leffler B and Frost F: The role of intracavernous injection of vasoactive medications for the restoration of erection in spinal cord injured males: a three year follow up. Paraplegia 1992; 30: 118.

765. Chao R and Clowers DE: Experience with intracavernosal tri-mixture for the management of neurogenic erectile dysfunction. Arch Phys Med Rehabil 1994; 75: 276.

766. Earle CM, Keogh EJ, Ker JK et al: The role of intracavernosal vasoactive agents to overcome impotence due to spinal cord injury. Paraplegia 1992; 30: 273.

767. Hirsch IH, Smith RL, Chancellor MB et al: Use of intracavernous injection of prostaglandin E1 for neuropathic erectile dysfunction. Paraplegia 1994; 32: 661.

768. Kapoor VK, Chahal AS, Jyoti SP et al: Intracavernous papaverine for impotence in spinal cord injured patients. Paraplegia 1993; 31: 675.

769. Sidi AA, Cameron JS, Dykstra DD et al: Vasoactive intracavernous pharmacotherapy for the treatment of erectile impotence in men with spinal cord injury. J Urol 1987; 138: 539.

770. Tang SF, Chu NK and Wong MK: Intracavernous injection of prostaglandin E1 in spinal cord injured patients with erectile dysfunction. A preliminary report. Paraplegia 1995; 33: 731.

771. Zaslau S, Nicolis C, Galea G et al: A simplified pharmacologic erection program for patients with spinal cord injury. J Spinal Cord Med 1999; 22: 303.

772. Derouet H, Meeth M and Bewermeier H: Experience with a papaverine/phentolamine/prostaglandin E1-mixture in non-responders to autoinjection therapy. Aktuelle Urologie 1996; 5: 271.

773. Akdemir F, Okulu E and Kayigil O: Long-term outcomes of AMS Spectra® penile prosthesis implantation and satisfaction rates. Int J Impot Res 2017; 5: 184.

774. Casabe AR, Sarotto N, Gutierrez C et al: Satisfaction assessment with malleable prosthetic implant of Spectra (AMS) and Genesis (Coloplast) models. Int J Impot Res 2016; 28: 228.

775. Akin-Olugbade O, Parker M, Guhring P et al: Determinants of patient satisfaction following penile prosthesis surgery. J Sex Med 2006; 3: 743.

776. Al-Najar A, Naumann CM, Kaufmann S et al: Should being aged over 70 years hinder penile prosthesis implantation? BJU Int 2009; 104: 834.

777. Altunkol A, Erçil H, Şener NC et al: Clinical evaluation of outcomes of penile prosthesis implantation and partner satisfaction. Erciyes Tip Dergisi 2014; 36: 148.

778. Anafarta K, Safak M, Beduk Y et al: Clinical experience with inflatable and malleable penile implants in 104 patients. Urol Int 1996; 56: 100.

779. Bae JH, Song PH, Kim HT et al: Assessment of erectile and ejacul*tory function after penile prosthesis implantation. Korean J Urol 2010; 51: 202.

780. Bettocchi C, Palumbo F, Spilotros M et al: Patient and partner satisfaction after AMS inflatable penile prosthesis implant. J Sex Med 2010; 7: 304.

781. Borges F, Hakim L and Kline C: Surgical technique to maintain penile length after insertion of an inflatable penile prosthesis via infrapubic approach. J Sex Med 2006; 3: 550.

782. Bozkurt IH, Arslan B, Kozacioglu Z et al: Does the etiology affect the outcome and satisfaction rates of penile prosthesis implantation surgery? Kaohsiung J Med Sci 2014; 30: 570.

783. Bozkurt IH, Arslan B, Yonguc T et al: Patient and partner outcome of inflatable and semi-rigid penile prosthesis in a single institution. Int Braz J Urol 2015; 41: 535.

784. Brinkman MJ, Henry GD, Wilson SK et al: A survey of patients with inflatable penile prostheses for satisfaction. J Urol 2005; 174: 253.

785. Cakan M, Demirel F, Karabacak O et al: Risk factors for penile prosthetic infection. Int Urol Nephrol 2003; 35: 209.

786. Carson CC, Mulcahy JJ and Govier FE: Efficacy, safety and patient satisfaction outcomes of the AMS 700CX inflatable penile prosthesis: results of a long-term multicenter study. AMS 700CX Study Group. J Urol 2000; 164: 376.

787. Carson CC 3rd, Mulcahy JJ and Harsch MR: Long-term infection outcomes after original antibiotic impregnated inflatable penile prosthesis implants: up to 7.7 years of followup. J Urol 2011; 185: 614.

788. Carvalheira A, Santana R and Pereira NM: Why are men satisfied or dissatisfied with penile implants? A mixed method study on satisfaction with penile prosthesis implantation. J Sex Med 2015; 12: 2474.

789. Chiang HS, Liao CH and Chang ML: Benefits of antibiotic-impregnated inflatable penile prosthesis (InhibiZone®) in patients at high risk of infection in Taiwan. Urological Science 2016; 27: 144.

790. Chiang HS, Wu CC and Wen TC: 10 years of experience with penile prosthesis implantation in Taiwanese patients. J Urol 2000; 163: 476.

791. Chin CM, Jacinto HA and Lim PHC: Penile implant surgery - review of local series. Asian Journal of Surgery 1999; 22: 402.

792. Deuk Choi Y, Jin Choi Y, Hwan Kim J et al: Mechanical reliability of the AMS 700CXM inflatable penile prosthesis for the treatment of male erectile dysfunction. J Urol 2001; 165: 822.

793. Chung E, Solomon M, Deyoung L et al: Clinical outcomes and patient satisfaction rates among elderly male aged ≥75 years with inflatable penile prosthesis implant for medically refractory erectile dysfunction. World J Urol 2013; 1: 173.

794. Chung E, Van CT, Wilson I et al: Penile prosthesis implantation for the treatment for male erectile dysfunction: clinical outcomes and lessons learnt after 955 procedures. World J Urol 2013; 31: 591.

795. Daitch JA, Angermeier KW, Lakin MM et al: Long-term mechanical reliability of AMS 700 series inflatable penile prostheses: Comparison of CX/CXM and Ultrex cylinders. J Urol 1997; 158: 1400.

796. Dhabuwala C, Sheth S and Zamzow B: Infection rates of ifampin/gentamicin-coated Titan Coloplast penile implants. Comparison with Inhibizone-impregnated AMS penile implants. J Sex Med 2011; 8: 315.

797. Dhar NB, Angermeier KW and Montague DK: Long-term mechanical reliability of AMS 700CX/CXM inflatable penile prosthesis. J Urol 2006; 176: 2599.

798. Dorflinger T and Bruskewitz R: AMS malleable penile prosthesis. Urology 1986; 28: 480.

799. Droggin D, Shabsigh R and Anastasiadis AG: Antibiotic coating reduces penile prosthesis infection. J Sex Med 2005; 2: 565.

800. Earle CM, Watters GR, Tulloch AG et al: Complications associated with penile implants used to treat impotence. Aust N Z J Surg 1989; 59: 959.

801. Eid JF, Wilson SK, Cleves M et al: Coated implants and "no touch" surgical technique decreases risk of infection in inflatable penile prosthesis implantation to 0.46%. Urology 2012; 79: 1310.

802. Enemchukwu EA, Kaufman MR, Whittam BM et al: Comparative revision rates of inflatable penile prostheses using woven Dacron® fabric cylinders. J Urol 2013; 190: 2189.

803. Fathy A, Shamloul R, AbdelRahim A et al: Experience with Tube (Promedon) malleable penile implant. Urol Int 2007; 79: 244.

804. Fein RL: GFS Mark II inflatable penile prosthesis: four-year clinical study. Urology 1994; 43: 209.

805. Ferguson KH and Cespedes RD: Prospective long-term results and quality-of-life assessment after DURA-II penile prosthesis placement. Urology 2003; 61: 437.

806. Furlow WL, Goldwasser B and Gundian JC: Implantation of model AMS 700 penile prosthesis: long-term results. J Urol 1988; 139: 741.

807. Knoll LD, Furlow WL and Motley RC: Clinical experience implanting an inflatable penile prosthesis with controlled-expansion cylinder. Urology 1990; 36: 502.

808. Garber BB and Marcus SM: Does surgical approach affect the incidence of inflatable penile prosthesis infection? Urology 1998; 52: 291.

809. Garber BB: Inflatable penile prosthesis: results of 150 cases. Br J Urol 1996; 78: 933.

810. Garber BB: Outpatient inflatable penile prosthesis insertion. Urology 1997; 49: 600. 811. Garber BB: Inflatable penile prosthesis: site-specific malfunction analysis. Int J Impot Res 2003; 15: 22.

812. Gentile G, Franceschelli A, Massenio P et al: Patient's satisfaction after 2-piece inflatable penile prosthesis implantation: an Italian multicentric study. Arch Ital Urol Androl 2016; 88: 1.

813. Goldstein I, Bertero EB, Kaufman JM et al: Early experience with the first pre-connected 3-piece inflatable penile prosthesis: the Mentor Alpha-1. J Urol 1993; 150: 1814.

814. Goldstein I, Newman L, Baum N et al: Safety and efficacy outcome of Mentor Alpha-1 inflatable penile prosthesis implantation for impotence treatment. J Urol 1997; 157: 833.

815. Grewal S, Vetter J, Brandes SB et al: A population-based analysis of contemporary rates of reoperation for penile prosthesis procedures. Urology 2014; 84: 112.

816. Henry GD, Brinkman MJ, Mead SF et al: A survey of patients with inflatable penile prostheses: assessment of timing and frequency of intercourse and analysis of implant durability. J Sex Med 2012; 9: 1715.

817. Henry GD, Carrion R, Jennermann C et al: Prospective evaluation of postoperative penile rehabilitation: penile length/girth maintenance 1 year following Coloplast Titan inflatable penile prosthesis. J Sex Med 2015; 12: 1298.

818. Hollenbeck BK, Miller DC and Ohl DA: The utility of lockout valve reservoirs in preventing autoinflation in penile prostheses. Int Urol Nephrol 2002; 34: 379.

819. Holloway FB and Farah RN: Intermediate term assessment of the reliability, function and patient satisfaction with the AMS700 Ultrex penile prosthesis. J Urol 1997; 157: 1687.

820. Jarow JP: Risk factors for penile prosthetic infection. J Urol 1996; 156: 402.

821. Jensen JB, Larsen EH, Kirkeby HJ et al: Clinical experience with the Mentor Alpha-1 inflatable penile prosthesis: report on 65 patients. Scand J Urol Nephrol 2005; 39: 69.

822. Jensen JB, Madsen SS, Larsen EH et al: Patient and partner satisfaction with the Mentor Alpha-1 inflatable penile prosthesis. Scand J Urol Nephrol 2005; 39: 66.

823. Ji YS, Ko YH, Song PH et al: Long-term survival and patient satisfaction with inflatable penile prosthesis for the treatment of erectile dysfunction. Korean J Urol 2015; 56: 461.

824. Kilicarslan H, Kaynak Y, Gokcen K et al: Comparison of patient satisfaction rates for the malleable and two piece-inflatable penile prostheses. Turk J Urol 2014; 40: 207.

825. Kim DS, Yang KM, Chung HJ et al: AMS 700CX/CXM inflatable penile prosthesis has high mechanical reliability at long-term follow-up. J Sex Med 2010; 7: 2602.

826. Kucuk EV, Tahra A, Bindayi A et al: Erectile dysfunction patients are more satisfied with penile prosthesis implantation compared with tadalafil and intracavernosal injection treatments. Andrology 2016; 4: 952.

827. Lacy J, Walker J, Gupta S et al: Risk factors for removal or revision of penile prostheses in the veteran population. Urology 2016; 98: 189.

828. Levine LA, Estrada CR and Morgentaler A: Mechanical reliability and safety of, and patient satisfaction with the Ambicor inflatable penile prosthesis: results of a 2 center study. J Urol 2001; 166: 932.

829. Liberman SN, Gomella LG and Hirsch IH: Experience with the Ultrex and Ultrex Plus inflatable penile prosthesis: new implantation techniques and surgical outcome. Int J Impot Res 1998; 10: 175.

830. Lin AN: Implantation of penile prosthesis: Clinical experience with 105 cases. Asian J Surg 1989; 12: 125.

831. Lindeborg L, Fode M, Fahrenkrug L et al: Satisfaction and complications with the Titan® one-touch release penile implant. Scand J Urol 2014; 48: 105.

832. Lledo-Garcia E, Jara-Rascon J, Moncada Iribarren I et al: Penile prosthesis first and replacement surgeries: analysis of patient and partner satisfaction. J Sex Med 2015; 12: 1646.

833. Lotan Y, Roehrborn CG, McConnell JD et al: Factors influencing the outcomes of penile prosthesis surgery at a teaching institution. Urology 2003; 62: 918.

834. Lubensky JD: Outpatient 3-piece inflatable penile prosthesis. J Urol 1991; 145: 1176.

835. Lux M, Reyes-Vallejo L, Morgentaler A et al: Outcomes and satisfaction rates for the redesigned 2-piece penile prosthesis. J Urol 2007; 177: 262.

836. Lynch MJ, Scott GM, Inglis JA et al: Reducing the loss of implants following penile prosthetic surgery. Br J Urol 1994; 73: 423.

837. Malloy TR, Wein AJ and Carpiniello VL: Reliability of AMS 700 inflatable penile prosthesis. Urology 1986; 28: 385.

838. Manning M, Martinez FJ, Alken P et al: Spontaneous tumescence after implantation of three-piece hydraulic penile prostheses: a short-term experience. Int J Impot Res 2003; 15: 152.

839. Mansi MK: Penile prosthesis: long-term follow up. Saudi Med J 1996; 17: 365.

840. McLaren RH and Barrett DM: Patient and partner satisfaction with the AMS 700 penile prosthesis. J Urol 1992; 147: 62.

841. Merrill DC: Clinical experience with the mentor inflatable penile prosthesis in 301 patients. J Urol 1988; 140: 1424.

842. Milbank AJ, Montague DK, Angermeier KW et al: Mechanical failure of the American Medical Systems Ultrex inflatable penile prosthesis: before and after 1993 structural modification. J Urol 2002; 167: 2502.

843. Minervini A, Ralph DJ and Pryor JP: Outcome of penile prosthesis implantation for treating erectile dysfunction: experience with 504 procedures. BJU Int 2006; 97: 129.

844. Miranda-Sousa A, Keating M, Moreira S et al: Concomitant ventral phalloplasty during penile implant surgery: a novel procedure that optimizes patient satisfaction and their perception of phallic length after penile implant surgery. J Sex Med 2007; 4: 1494.

845. Mirheydar H, Zhou T, Chang DC et al: Reoperation rates for penile prosthetic surgery. J Sex Med 2016; 13: 129.

846. Moncada I, Martinez-Salamanca JI, Jara J et al: Inflatable penile prosthesis implantation without corporeal dilation: a cavernous tissue sparing technique. J Urol 2010; 183: 1123.

847. Montorsi F, Rigatti P, Carmignani G et al: AMS three-piece inflatable implants for erectile dysfunction: a long-term multi-institutional study in 200 consecutive patients. Eur Urol 2000; 37: 50.

848. Gittens P, Moskovic DJ, Avila D, Jr. et al: Favorable female sexual function is associated with patient satisfaction after inflatable penile prosthesis implantation. J Sex Med 2011; 8: 1996.

849. Moul JW and McLeod DG: Experience with the AMS 600 malleable penile prosthesis. J Urol 1986; 135: 929.

850. Mulhall JP, Ahmed A, Branch J et al: Serial assessment of efficacy and satisfaction profiles following penile prosthesis surgery. J Urol 2003; 169: 1429.

851. Natali A, Olianas R and Fisch M: Penile implantation in Europe: successes and complications with 253 implants in Italy and Germany. J Sex Med 2008; 5: 1503.

852. Negro CL, Paradiso M, Rocca A et al: Implantation of AMS 700 LGX penile prosthesis preserves penile length without the need for penile lengthening procedures. Asian J Androl 2016; 18: 114.

853. Nickas ME, Kessler R and Kabalin JN: Long-term experience with controlled expansion cylinders in the AMS 700CX inflatable penile prosthesis and comparison with earlier versions of the Scott inflatable penile prosthesis. Urology 1994; 44: 400.

854. Nukui F, Okamoto S, Nagata M et al: Complications and reimplantation of penile implants. Int J Urol 1997; 4: 52.

855. Ohl DA, Brock G, Ralph D et al: Prospective evaluation of patient satisfaction, and surgeon and patient trainer assessment of the Coloplast Titan one touch release three-piece inflatable penile prosthesis. J Sex Med 2012; 9: 2467.

856. Paranhos M, Andrade E, Antunes AA et al: Penile prosthesis implantation in an academic institution in Latin America. Int Braz J Urol 2010; 36: 591.

857. Pescatori E, Alei G, Antonini G et al: INSIST-ED: Italian Society of Andrology registry on penile prosthesis surgery. First data analysis. Arch Ital Urol Androl 2016; 88: 122.

858. Pozza D, Pozza M, Musy M et al: 500 penile prostheses implanted by a surgeon in Italy in the last 30 years. Arch Ital Urol Androl 2015; 87: 216. 859. Randrup ER: Clinical experience with 180 inflatable penile prostheses. South Med J 1995; 88: 47.

860. Randrup E, Wilson S, Mobley D et al: Clinical experience with Mentor Alpha I inflatable penile prosthesis. Report on 333 cases. Urology 1993; 42: 305.

861. Rogers E and Murphy DM: Use of the AMS inflatable penile prosthesis in the management of erectile impotence. Ir Med J 1997; 90: 105.

862. Salama N: Satisfaction with the malleable penile prosthesis among couples from the Middle East--is it different from that reported elsewhere? Int J Impot Res 2004; 16: 175.

863. Salem EA, Wilson SK, Neeb A et al: Mechanical reliability of AMS 700 CX improved by parylene coating. J Sex Med 2009; 6: 2615.

864. Saypol DC, Uhran CM and Stockman JC: Treatment of erectile failure with inflatable prostheses: three-year experience. N J Med 1987; 84: 191.

865. Scarzella GI: Reliability of the AMS inflatable prostheses in 444 consecutive cases. Arch Ital Urol Androl 1993; 65: 661.

866. Scarzella GI: Cylinder reliability of inflatable penile prosthesis. Experience with distensible and nondistensible cylinders in 325 patients. Urology 1988; 31: 486.

867. Serefoglu EC, Mandava SH, Gokce A et al: Long-term revision rate due to infection in hydrophilic-coated inflatable penile prostheses: 11-year follow-up. J Sex Med 2012; 9: 2182.

868. Sevinc C, Ozkaptan O, Balaban M et al: Outcome of penile prosthesis implantation: are malleable prostheses an appropriate treatment option in patients with erectile dysfunction caused by prior radical surgery? Asian J Androl 2016; 4: 477.

869. Simsek A, Kucuktopcu O, Ozgor F et al: Self and partner satisfaction rates after 3 part inflatable penile prosthesis implantation. Arch Ital Urol Androl 2014; 86: 219.

870. Song WD, Yuan YM, Cui WS et al: Penile prosthesis implantation in Chinese patients with severe erectile dysfunction: 10-year experience. Asian J Androl 2013; 15: 658.

871. Tefilli MV, Dubocq F, Rajpurkar A et al: Assessment of psychosexual adjustment after insertion of inflatable penile prosthesis. Urology 1998; 52: 1106.

872. Thomas AZ, Carrol R, Manecksha RP et al: Extended long term functional outcome of inflatable penile prosthesis in a single institution. Ir Med J 2011; 104: 53.

873. Vakalopoulos I, Kampantais S, Ioannidis S et al: High patient satisfaction after inflatable penile prostheses implantation correlates with female partner satisfaction. J Sex Med 2013; 10: 2774.

874. Vitarelli A, Divenuto L, Fortunato F et al: Long term patient satisfaction and quality of life with AMS700CX inflatable penile prosthesis. Arch Ital Urol Androl 2013; 85: 133.

875. Whalen RK and Merrill DC: Patient satisfaction with mentor inflatable penile prosthesis. Urology 1991; 37: 531.

876.Wilson SK and Delk JR, 2nd: Inflatable penile implant infection: predisposing factors and treatment suggestions. J Urol 1995; 153: 659.

877. Wilson SK, Carson CC, Cleves MA et al: Quantifying risk of penile prosthesis infection with elevated glycosylated hemoglobin. J Urol 1998; 159: 1537.

878. Wilson SK, Cleves MA and Delk JR 2nd: Comparison of mechanical reliability of original and enhanced Mentor Alpha I penile prosthesis. J Urol 1999; 162: 715.

879. Wilson SK, Delk JR, Salem EA et al: Long-term survival of inflatable penile prostheses: single surgical group experience with 2,384 first-time implants spanning two decades. J Sex Med 2007; 4: 1074.

880. Woodworth BE, Carson CC and Webster GD: Inflatable penile prosthesis: effect of device modification on functional longevity. Urology 1991; 38: 533.

881. Zabar KJ, Ahmadi A and Jalal AA: Penile prosthesis implantation for the treatment of erectile dysfunction. Bahrain Medical Bulletin 2009; 31: 2.

882. Zhu YC, Zhao JL, Wu YG et al: Clinical features and treatment options for Chinese patients with severe primary erectile dysfunction. Urology 2010; 76: 387.

883. Antonini G, Busetto GM, De Berardinis E et al: Penile prosthesis implant for erectile dysfunction: a new minimally invasive infrapubic surgical technique. Arch Ital Urol Androl 2015; 87: 322.

884. Menard J, Tremeaux JC, Faix A et al: Erectile function and sexual satisfaction before and after penile prosthesis implantation in radical prostatectomy patients: a comparison with patients with vasculogenic erectile dysfunction. J Sex Med 2011; 8: 3479.

885. Kim YD, Yang SO, Lee JK et al: Usefulness of a malleable penile prosthesis in patients with a spinal cord injury. Int J Urol 2008; 15: 919.

886. Kramer AC and Schweber A: Patient expectations prior to Coloplast Titan penile prosthesis implant predicts postoperative satisfaction. J Sex Med 2010; 7: 2261.

887. Nehra A, Carson CC 3rd, Chapin AK et al: Long-term infection outcomes of 3-piece antibiotic impregnated penile prostheses used in replacement implant surgery. J Urol 2012; 188: 899.

888. Mulcahy JJ and Carson CC 3rd: Long-term infection rates in diabetic patients implanted with antibiotic-impregnated versus nonimpregnated inflatable penile prostheses: 7-year outcomes. Eur Urol 2011; 60: 167.

889. Christodoulidou M and Pearce I: Infection of penile prostheses in patients with diabetes mellitus. Surg Infect (Larchmt) 2016; 17: 2.

890. Deveci S, Martin D, Parker M et al: Penile length alterations following penile prosthesis surgery. Eur Urol 2007; 51: 1128.

891. Wang R, Howard GE, Hoang A et al: Prospective and long-term evaluation of erect penile length obtained with inflatable penile prosthesis to that induced by intracavernosal injection. Asian J Androl 2009; 11: 411.

892. Levine LA and Rybak J: Traction therapy for men with shortened penis prior to penile prosthesis implantation: a pilot study. J Sex Med 2011; 8: 2112.

893. Canguven O, Talib RA, Campbell J et al: Is the daily use of vacuum erection device for a month before penile prosthesis implantation beneficial? A randomized controlled trial. Andrology 2017; 5: 103.

894. Pahlajani G, Raina R, Jones S et al: Vacuum erection devices revisited: its emerging role in the treatment of erectile dysfunction and early penile rehabilitation following prostate cancer therapy. J Sex Med 2012; 9: 1182.

895. Tsambarlis PN, Chaus F and Levine LA: Successful placement of penile prostheses in men with severe corporal fibrosis following vacuum therapy protocol. J Sex Med 2017; 14: 44.

896. Henry GD, Kansal NS, Callaway M et al: Centers of excellence concept and penile prostheses: an outcome analysis. J Urol 2009; 181: 1264.

897. Hakky TS, Suber J, Henry G et al: Penile enhancement procedures with simultaneous penile prosthesis placement. Adv Urol 2012; 2012: doi:10.1155/2012/314612.

898. Chew KK and Stuckey BG: Use of transurethral alprostadil (MUSE) (prostaglandin E1) for glans tumescence in a patient with penile prosthesis. Int J Impot Res 2000; 12: 195.

899. Benevides MD and Carson CC: Intraurethral application of alprostadil in patients with failed inflatable penile prosthesis. J Urol 2000; 163: 785.

900. Mulhall JP, Jahoda A, Aviv N et al: The impact of sildenafil citrate on sexual satisfaction profiles in men with a penile prosthesis in situ. BJU Int 2004; 93: 97.

901. Pryor MB, Carrion R, Wang R et al: Patient satisfaction and penile morphology changes with postoperative penile rehabilitation 2 years after Coloplast Titan prosthesis. Asian J Androl 2016; 18: 754.

902. Anafarta K, Aydos K and Yaman O: Is deep dorsal vein arterialization an alternative surgical approach to treat venogenic impotence? Urol Int 1997; 59: 109.

903. Austoni E, Colombo F, Mantovani F et al: Venous surgery in erectile dysfunction: therapeutic strategy and results. Urol Int 1992; 49: 63.

904. Balko A, Malhotra CM and Wincze JP: Deep-penile-vein arterialization for arterial and venous impotence. Arch Surg 1986; 121: 774.

905. Cookson MS, Phillips DL, Huff ME et al: Analysis of microsurgical penile revascularization results by etiology of impotence. J Urol 1993; 149: 1308.

906. Crespo E, Bove D, Farrell G et al: Revascularization of the cavernous body in vasculogenic sexual male impotence with a new microsurgical technique. Cardiovasc Res Cent Bull 1983; 22: 29.

907. DePalma RG, Olding M, Yu GW et al: Vascular interventions for impotence: lessons learned. J Vasc Surg 1995; 21: 576.

908. Frankovicova M and Thoma A: Microvascular treatment of impotence. Plast Reconstr Surg 1993; 91: 99.

909. Grasso M, Lania C, Castelli M et al: Deep dorsal vein arterialization in vasculogenic impotence: our experience. Arch Ital Urol Nefrol Androl 1992; 64: 309.

910. Hatzinger M, Seemann O, Grenacher L et al: Laparoscopy-assisted penile revascularization: a new method. J Endourol 1997; 11: 269.

911. Janssen T, Sarramon JP, Rischmann P et al: Microsurgical arterio-arterial and arterio-venous penile revascularization in patients with pure arteriogenic impotence. Br J Urol 1994; 73: 561.

912. Jarow JP and DeFranzo AJ: Long-term results of arterial bypass surgery for impotence secondary to segmental vascular disease. J Urol 1996; 156: 982.

913. Kaufman JM, Kaufman JL and Fitch WP 3rd: Deep dorsal vein arterialization in arteriogenic impotence: use of the dorsal artery as a neoarterial source. Int J Impot Res 1995; 7: 157.

914. Kawanishi Y, Kimura K, Nakanishi R et al: Penile revascularization surgery for arteriogenic erectile dysfunction: the long-term efficacy rate calculated by survival analysis. BJU Int 2004; 94: 361.

915. Kayigil O, Agras K and Okulu E: Is deep dorsal vein arterialization effective in elderly patients? Int Urol Nephrol 2008; 40: 125.

916. Kayigil O, Ahmed SI and Metin A: Deep dorsal vein arterialization in pure cavernoocclusive dysfunction. Eur Urol 2000; 37: 345.

917. Kayigil O, Okulu E, Aldemir M et al: Penile revascularization in vasculogenic erectile dysfunction (ED): long-term follow-up. BJU Int 2012; 109: 109.

918. Knoll LD: Penile dorsal vein arterialization in managing venogenic impotence. Tech Urol 1995; 1: 157.

919. Lizza EF and Zorgniotti AW: Experience with the long-term effect of microsurgical penile revascularization. Int J Impot Res 1994; 6: 145.

920. Lobelenz M, Junemann KP, Kohrmann KU et al: Penile revascularization in nonresponders to intracavernous injections using a modified microsurgical technique. Eur Urol 1992; 21: 120.

921. Lukkarinen O, Tonttila P, Hellstrom P et al: Non-prosthetic surgery in the treatment of erectile dysfunction. A retrospective study of 45 impotent patients in the University of Oulu. Scand J Urol Nephrol 1998; 32: 42.

922. Manning M, Junemann KP, Scheepe JR et al: Long-term followup and selection criteria for penile revascularization in erectile failure. J Urol 1998; 160: 1680.

923. Melman A and Riccardi R, Jr.: The success of microsurgical penile revascularization in treating arteriogenic impotence. Int J Impot Res 1993; 5: 47.

924. Michal V, Kramar R, Pospichal J et al: Arterial epigastricocavernous anastomosis for the treatment of sexual impotence. World J Surg 1977; 1: 515.

925. Munarriz R, Uberoi J, Fantini G et al: Microvascular arterial bypass surgery: long-term outcomes using validated instruments. J Urol 2009; 182: 643.

926. Sarramon JP, Bertrand N, Malavaud B et al: Microrevascularisation of the penis in vascular impotence. Int J Impot Res 1997; 9: 127.

927. Sarramon JP, Malavaud B, Braud F et al: Evaluation of male sexual function by the International Index of Erectile Function after deep dorsal vein arterialization of the penis. J Urol 2001; 166: 576.

928. Schramek P, Engelmann U and Kaufmann F: Microsurgical arteriovenous revascularization in the treatment of vasculogenic impotence. J Urol 1992; 147: 1028.

929. Sohn M, Sikora R, Bohndorf K et al: Selective microsurgery in arteriogenic erectile failure. World J Urol 1990; 8: 104.

930. Vardi Y, Gruenwald I, Gedalia U et al: Evaluation of penile revascularization for erectile dysfunction: a 10-year follow-up. Int J Impot Res 2004; 16: 181.

931. Virag R and Bennett AH: Arterial and venous surgery for vasculogenic impotence: a combined French and American experience. Arch Ital Urol Nefrol Androl 1991; 63: 95.

932. Wespes E, Corbusier A, Delcour C et al: Deep dorsal vein arterialisation in vascular impotence. Br J Urol 1989; 64: 535.

933. Wespes E, Wildschutz T, Roumeguere T et al: The place of surgery for vascular impotence in the third millennium. J Urol 2003; 170: 1284.

934. Zumbe J, Drawz G, Wiedemann A et al: Indications for penile revascularization and long-term results. Andrologia 1999; 31 Suppl 1: 83.

935. Munarriz R: Penile microvascular arterial bypass surgery: indications, outcomes, and complications. ScientificWorldJournal 2010; 10: 1556.

936. Dabaja AA, Teloken P and Mulhall JP: A critical analysis of candidacy for penile revascularization. J Sex Med 2014; 11: 2327.

937. Afsar H, Metin A, Sozduyar N et al: Erectile dysfunction due to venous incompetence treated by dorsal vein ligation. Int Urol Nephrol 1992; 24: 65.

938. Anafarta K, Beduk Y, Aydos K et al: Treatment of impotence due to venous leakage by resection of the deep dorsal vein of the penis. Urol Int 1992; 48: 332.

939. Bar-Moshe O and Vandendris M: Surgical approach of venous leakage. Urol Int 1992; 49: 19.

940. Berardinucci D, Morales A, Heaton JP et al: Surgical treatment of penile veno-occlusive dysfunction: is it justified? Urology 1996; 47: 88.

941. Cakan M, Yalcinkaya F, Demirel F et al: Is dorsale penile vein ligation (DPVL) still a treatment option in veno-occlusive dysfunction? Int Urol Nephrol 2004; 36: 381.

942. Cayan S: Primary penile venous leakage surgery with crural ligation in men with erectile dysfunction. J Urol 2008; 180: 1056.

943. Chen SC, Hsieh CH, Hsu GL et al: The progression of the penile vein: could it be recurrent? J Androl 2005; 26: 53.

944. Claes H and Baert L: Pelvic floor exercise versus surgery in the treatment of impotence. Br J Urol 1993; 71: 52.

945. Claro Jde A, de Lima ML and Netto Junior N: Surgical treatment of veno-occlusive dysfunction: evaluation of short-term and long-term results. Rev Paul Med 1992; 110: 280.

946. Flores S, Tal R, O'Brien K et al: Outcomes of crural ligation surgery for isolated crural venous leak. J Sex Med 2011; 8: 3495.

947. Fowlis GA, Sidhu PS, Jager HR et al: Preliminary report--combined surgical and radiological penile vein occlusion for the management of impotence caused by venous-sinusoidal incompetence. Br J Urol 1994; 74: 492.

948. Freedman AL, Costa Neto F, Mehringer CM et al: Long-term results of penile vein ligation for impotence from venous leakage. J Urol 1993; 149: 1301.

949. Gilbert P, Sparwasser C, Beckert R et al: Venous surgery in erectile dysfunction. The role of dorsal-penile-vein ligation and spongiosolysis for impotence. Urol Int 1992; 49: 40.

950. Hassan AA, Hassouna MM and Elhilali MM: Long-term results of penile venous ligation for corporeal venous occlusive dysfunction. Can J Surg 1995; 38: 537.

951. Hirsch M, Lubetsky R, Goldman H et al: Dorsal vein sclerosis as a predictor of outcome in penile venous ligation surgery. J Urol 1993; 150: 1810.

952. Hsu GL, Chen HS, Hsieh CH et al: Clinical experience of a refined penile venous stripping surgery procedure for patients with erectile dysfunction: is it a viable option? J Androl 2010; 31: 271.

953. Hwang TI and Yang CR: Penile vein ligation for venogenic impotence. Eur Urol 1994; 26: 46.

954. Katzenwadel A, Popken G and Wetterauer U: Penile venous surgery for cavernosal venous leakage: long-term results and retrospective studies. Urol Int 1993; 50: 71.

955. Kerfoot WW, Carson CC, Donaldson JT et al: Investigation of vascular changes following penile vein ligation. J Urol 1994; 152: 884.

956. Kim ED and McVary KT: Long-term results with penile vein ligation for venogenic impotence. J Urol 1995; 153: 655.

957. Knoll LD, Furlow WL and Benson RC: Penile venous ligation surgery for the management of cavernosal venous leakage. Urol Int 1992; 49: 33.

958. Kropman RF, Lycklama Nijeholt AAAB, Odink HF et al: Treatment of impotence caused by veno-occlusive dysfunction with detachable balloons and coils in combination with resection of the deep dorsal vein: comparison with resection of the deep dorsal vein only. World J Urol 1992; 10: 226.

959. Lewis RW: Results of surgery for veno-occlusive disease. J Sex Marital Ther 1991; 17: 129.

960. Lunglmayr G, Nachtigall M and Gindl K: Long-term results of deep dorsal penile vein transsection in venous impotence. Eur Urol 1988; 15: 209.

961. McLoughlin J, Asopa R and Williams G: Surgical treatment of venous leakage: medium-term follow-up. Eur Urol 1993; 23: 352.

962. Miwa Y, Shioyama R, Itou Y et al: Pelvic venoablation with ethanol for the treatment of erectile dysfunction due to veno-occlusive dysfunction. Urology 2001; 58: 76.

963. Montague DK, Angermeier KW, Lakin MM et al: Penile venous ligation in 18 patients with 1 to 3 years of followup. J Urol 1993; 149: 306.

964. Motiwala HG, Patel DD, Joshi SP et al: Experience with penile venous surgery. Urol Int 1993; 51: 9.

965. Netto Jr NR, Cara A, Reinato JAS et al: Cavernosometry: corroboratory method to surgical treatment of impotence due to venous leakage. Urology 1990; 35: 35.

966. Ng FC, Ruan XQ, Wong HT et al: Venous ligation for cavernous leak impotence--a report on 30 cases. Ann Acad Med Singapore 1995; 24: 716.

967. Nikoobakht M, Saraji A and Meysamie A: Preoperative corporal biopsy as a predictor of postoperative results in venoocclusive erectile dysfunction. Urol J 2005; 2: 160.

968. Parrott LH, Sholes AH, Rice JC et al: Penile vein dissection: a study of its long-term efficacy in impotence. World J Urol 1989; 7: 169.

969. Petrou S and Lewis RW: Management of corporal veno-occlusive dysfunction. Urol Int 1992; 49: 48.

970. Popken G, Katzenwadel A and Wetterauer U: Long-term results of dorsal penile vein ligation for symptomatic treatment of erectile dysfunction. Andrologia 1999; 31 Suppl 1: 77.

971. Rossman B, Mieza M and Melman A: Penile vein ligation for corporeal incompetence: an evaluation of short-term and long-term results. J Urol 1990; 144: 679.

972. Sasso F, Gulino G, Di Pinto A et al: Should venous surgery be still proposed or neglected? Int J Impot Res 1996; 8: 25.

973. Sasso F, Gulino G, Weir J et al: Patient selection criteria in the surgical treatment of veno-occlusive dysfunction. J Urol 1999; 161: 1145.

974. Schultheiss D, Truss MC, Becker AJ et al: Long-term results following dorsal penile vein ligation in 126 patients with veno-occlusive dysfunction. Int J Impot Res 1997; 9: 205.

975. Stief CG, Djamilian M, Truss MC et al: Prognostic factors for the postoperative outcome of penile venous surgery for venogenic erectile dysfunction. J Urol 1994; 151: 880.

976. Da Ros CT, Teloken C, Antonini CC et al: Long-term results of penile vein ligation for erectile dysfunction due to cavernovenous disease. Tech Urol 2000; 6: 172.

977. Torok A, Szekely J, Mark B et al: Surgical treatment of impotence due to venous outflow. Int Urol Nephrol 1989; 21: 485.

978. Treiber U and Gilbert P: Venous surgery in erectile dysfunction: a critical report on 116 patients. Urology 1989; 34: 22.

979. Tsai TC, Hsu GL, Chen SC et al: Analysis of the results of reconstructive surgery for vasculogenic impotence. Taiwan Yi Xue Hui Za Zhi 1988; 87: 182.

980. Vale JA, Feneley MR, Lees WR et al: Venous leak surgery: long-term follow-up of patients undergoing excision and ligation of the deep dorsal vein of the penis. Br J Urol 1995; 76: 192.

981. Wagenknecht LV: New treatment of increased venous drainage in organic impotence: ligation of internal iliac veins. Eur Urol 1989; 16: 172.

982. Weidner W, Weiske WH, Rudnick J et al: Venous surgery in veno-occlusive dysfunction: long-time results after deep dorsal vein resection. Urol Int 1992; 49: 24.

983. Wespes E and Schulman CC: Venous leakage: surgical treatment of a curable cause of impotence. J Urol 1985; 133: 796.

984. Wespes E, Moreira de Goes P, Sattar AA et al: Objective criteria in the long-term evaluation of penile venous surgery. J Urol 1994; 152: 888.

985. Wespes E, Delcour C, Preserowitz L et al: Impotence due to corporeal veno-occlusive dysfunction: long-term follow-up of venous surgery. Eur Urol 1992; 21: 115.

986. Williams G, Mulcahy MJ, Hartnell G et al: Diagnosis and treatment of venous leakage: a curable cause of impotence. Br J Urol 1988; 61: 151.

987. Yu GW, Schwab FJ, Melograna FS et al: Preoperative and postoperative dynamic cavernosography and cavernosometry: objective assessment of venous ligation for impotence. J Urol 1992; 147: 618.

988. Vardi Y, Appel B, Kilchevsky A et al: Does low intensity extracorporeal shock wave therapy have a physiological effect on erectile function? Short-term results of a randomized, double-blind, sham controlled study. J Urol 2012; 187: 1769.

989. Srini VS, Reddy RK, Shultz T et al: Low intensity extracorporeal shockwave therapy for erectile dysfunction: a study in an Indian population. Can J Urol 2015; 22: 7614.

990. Olsen AB, Persiani M, Boie S et al: Can low-intensity extracorporeal shockwave therapy improve erectile dysfunction? A prospective, randomized, double-blind, placebo-controlled study. Scand J Urol 2015; 49: 329.

991. Kalyvianakis D and Hatzichristou D: Low-intensity shockwave therapy improves hemodynamic parameters in patients with vasculogenic erectile dysfunction: a triplex ultrasonography-based sham-controlled trial. J Sex Med 2017; 14: 891.

992. Kitrey ND, Gruenwald I, Appel B et al: Penile low intensity shock wave treatment is able to shift PDE5i nonresponders to responders: a double-blind, sham controlled study. J Urol 2016; 195: 1550.

993. Yee CH, Chan ES, Hou SS et al: Extracorporeal shockwave therapy in the treatment of erectile dysfunction: a prospective, randomized, double-blinded, placebo controlled study. Int J Urol 2014; 21: 1041.

994. Fojecki GL, Tiessen S and Osther PJ: Effect of low-energy linear shockwave therapy on erectile dysfunction-a double-blinded, sham-controlled, randomized clinical trial. J Sex Med 2017; 14: 106.

995 Clavijo RI, Kohn TP, Kohn JR et al: Effects of low-intensity extracorporeal shockwave therapy on erectile dysfunction: a systematic review and meta-analysis. J Sex Med 2017; 14: 27.

996.Angulo JC, Arance I, de Las Heras MM et al: Efficacy of low-intensity shock wave therapy for erectile dysfunction: a systematic review and meta-analysis. Actas Urol Esp 2017; 41: 479.

997. Lu Z, Lin G, Reed-Maldonado A et al: Low-intensity extracorporeal shock wave treatment improves erectile function: a systematic review and meta-analysis. Eur Urol 2017; 71: 223.

998. Zou ZJ, Tang LY, Liu ZH et al: Short-term efficacy and safety of low-intensity extracorporeal shock wave therapy in erectile dysfunction: a systematic review and meta-analysis. Int Braz J Urol 2017; 43: 805.

999. Bahk JY, Jung JH, Han H et al: Treatment of diabetic impotence with umbilical cord blood stem cell intracavernosal transplant: preliminary report of 7 cases. Exp Clin Transplant 2010; 8: 150.

1000. Garber MG and Carlos, ND: Intracavernous administration of adipose stem cells: a new technique of treating erectile dysfunction in diabetic patient, preliminary report of 6 cases. MOJ Cell Sci Rep 2015; 1: 0001

1001. Yiou R, Hamidou L, Birebent B et al: Safety of intracavernous bone marrow-mononuclear cells for postradical prostatectomy erectile dysfunction: an open dose-escalation pilot study. Eur Urol 2016; 69: 988.

1002. Haahr MK, Jensen CH, Toyserkani NM et al: Safety and potential effect of a single intracavernous injection of autologous adipose-derived regenerative cells in patients with erectile dysfunction following radical prostatectomy: an open-label phase I clinical trial. EBioMedicine 2016; 5: 204.

1003. Levy JA, Marchand M, Iorio L et al: Determining the feasibility of managing erectile dysfunction in humans with placental-derived stem cells. J Am Osteopath Assoc 2016; 116: e1.

1004. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.

1005. https://www.hhs.gov/ohrp/regulations-and-policy/belmont-report/index.html

1006. Carter HB, Albertsen PC, Barry MJ, et al. Early Detection of Prostate Cancer: AUA Guideline.J Urol 2013; 2:419-426.

1007. Mulhall JP, Trost LW, Brannigan RE et al: Evaluation and Management of Testosterone Deficiency: AUA Guideline. J Urol 2018; doi 10.1016/j.juro.2018.03.115.

Erectile Dysfunction (ED) Guideline - American Urological Association (2024)

FAQs

What is the most successful treatment of erectile dysfunction? ›

Oral drugs or pills known as phosphodiesterase type-5 inhibitors are most often prescribed in the U.S. for ED (Viagra, Cialis, Levitra, Stendra) Testosterone Therapy (when low testosterone is detected in blood testing)

Get More Info Here ›

What is the best cream for erectile dysfunction? ›

What cream keeps you erect? Alprostadil creams like Vitaros work by improving blood flow to the penis and relaxing smooth muscle cells. This produces an erection firm enough for sex within 5-30 minutes in most men. Effects typically last 1-2 hours.

Show Me More ›

How long can the average man stay erect? ›

A penile erection can normally last anywhere from a few minutes to about half an hour. On average, men have five erections a night while they're sleeping, each lasting about 25 to 35 minutes (Youn, 2017).

Why can't I get rock hard anymore? ›

Causes of erectile dysfunction

This is usually caused by stress, tiredness or drinking too much alcohol, and it's nothing to worry about. It can also be a side effect of some medicines. If erectile dysfunction happens often, it may be caused by a condition such as: high blood pressure or high cholesterol.

Know More ›

What food helps you keep fully hard? ›

Cocoa, Dark Chocolate, Nuts & Other Flavonoid-Rich Foods

Nuts.
Tea and tea leaves.
Cocoa.
Dark chocolate.
Whole grains like oats.
Fruits like oranges, blueberries, apples, and peaches.
Vegetables like carrots and chili peppers.
Red wine.

Find Out More ›

How to increase blood flow to pennis? ›

Lifestyle changes like eating a nutritious diet, exercising, and managing stress may all help improve blood flow to the penis. Quitting smoking and limiting alcohol may also help. If natural remedies to improve erectile function don't work, see your healthcare provider.

What is a quick fix for erectile dysfunction? ›

What is the best way to fix erectile dysfunction?

Cardiovascular exercise. ...
Quitting smoking. ...
Talking to a sex therapist.
Oral medications that help increase blood flow to your penis, including sildenafil (Viagra®), vardenafil (Levitra®), tadalafil (Cialis®) or avanafil (Stendra®).

More items...

Show Me More ›

How to make pennis strong and healthy? ›

What can I do to keep my penis healthy?

Be sexually responsible. ...
Get vaccinated. ...
Stay physically active. ...
Make healthy choices. ...
Practice good hygiene. ...
Know your medicines. ...
Pay attention to your mental health. ...
Stop smoking and limit alcohol.

Apr 26, 2023

Learn More ›